<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Mirtazapine for fibromyalgia in adults - Welsch, P - 2018 | Cochrane Library</title> <meta content="Mirtazapine for fibromyalgia in adults - Welsch, P - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012708.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Mirtazapine for fibromyalgia in adults - Welsch, P - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012708.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012708.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Mirtazapine for fibromyalgia in adults" name="citation_title"/> <meta content="Patrick Welsch" name="citation_author"/> <meta content="Health Care Center for Pain Medicine and Mental Health" name="citation_author_institution"/> <meta content="Kathrin Bernardy" name="citation_author"/> <meta content="BG University Hospital Bergmannsheil GmbH, Ruhr University Bochum" name="citation_author_institution"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="Winfried Häuser" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="whaeuser@klinikum-saarbruecken.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD012708.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/08/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012708.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012708.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012708.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antidepressive Agents, Tricyclic [adverse effects, *therapeutic use]; Fibromyalgia [*drug therapy]; Mianserin [adverse effects, *analogs &amp; derivatives, therapeutic use]; Mirtazapine; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012708.pub2&amp;doi=10.1002/14651858.CD012708.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="l7AWCCEw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012708\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012708\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012708.pub2",title:"Mirtazapine for fibromyalgia in adults",firstPublishedDate:"Aug 6, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012708.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012708.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012708.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012708.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012708.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012708.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012708.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012708.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012708.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012708.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5112 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012708.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-sec-0083"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-sec-0077"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/appendices#CD012708-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/table_n/CD012708StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/table_n/CD012708StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Mirtazapine for fibromyalgia in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information#CD012708-cr-0004">Patrick Welsch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information#CD012708-cr-0005">Kathrin Bernardy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information#CD012708-cr-0006">Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information#CD012708-cr-0007">R Andrew Moore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information#CD012708-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Winfried Häuser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information/en#CD012708-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 August 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012708.pub2">https://doi.org/10.1002/14651858.CD012708.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012708-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012708-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012708-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012708-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012708-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012708-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012708-abs-0001" lang="en"> <section id="CD012708-sec-0001"> <h3 class="title" id="CD012708-sec-0001">Background</h3> <p>Fibromyalgia is a clinically defined chronic condition of unknown etiology characterised by chronic widespread pain, sleep disturbance, cognitive dysfunction, and fatigue. Many patients report high disability levels and poor quality of life. Drug therapy aims to reduce key symptoms, especially pain, and improve quality of life. The tetracyclic antidepressant, mirtazapine, may help by increasing serotonin and noradrenaline in the central nervous system (CNS). </p> </section> <section id="CD012708-sec-0002"> <h3 class="title" id="CD012708-sec-0002">Objectives</h3> <p>To assess the efficacy, tolerability and safety of the tetracyclic antidepressant, mirtazapine, compared with placebo or other active drug(s) in the treatment of fibromyalgia in adults. </p> </section> <section id="CD012708-sec-0003"> <h3 class="title" id="CD012708-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, SCOPUS, the US National Institutes of Health, and the World Health Organization (WHO) International Clinical Trials Registry Platform for published and ongoing trials, and examined reference lists of reviewed articles, to 9 July 2018. </p> </section> <section id="CD012708-sec-0004"> <h3 class="title" id="CD012708-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of any formulation of mirtazapine against placebo, or any other active treatment of fibromyalgia, in adults. </p> </section> <section id="CD012708-sec-0005"> <h3 class="title" id="CD012708-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted study characteristics, outcomes of efficacy, tolerability and safety, examined issues of study quality, and assessed risk of bias, resolving discrepancies by discussion. Primary outcomes were participant‐reported pain relief (at least 50% or 30% pain reduction), Patient Global Impression of Change (PGIC; much or very much improved), safety (serious adverse events), and tolerability (adverse event withdrawal). Other outcomes were health‐related quality of life (HRQoL) improved by 20% or more, fatigue, sleep problems, mean pain intensity, negative mood and particular adverse events. We used a random‐effects model to calculate risk difference (RD), standardised mean difference (SMD), and numbers needed to treat. We assessed the evidence using GRADE and created a 'Summary of findings' table. </p> </section> <section id="CD012708-sec-0006"> <h3 class="title" id="CD012708-sec-0006">Main results</h3> <p>Three studies with 606 participants compared mirtazapine with placebo (but not other drugs) over seven to 13 weeks. Two studies were at unclear or high risk of bias in six or seven of eight domains. We judged the evidence for all outcomes to be low‐ or very low‐quality because of poor study quality, indirectness, imprecision, risk of publication bias, and sometimes low numbers of events. </p> <p>There was no difference between mirtazapine and placebo for any primary outcome: participant‐reported pain relief of 50% or greater (22% versus 16%; RD 0.05, 95% confidence interval (CI) ‐0.01 to 0.12; three studies with 591 participants; low‐quality evidence); no data available for PGIC; only a single serious adverse event for evaluation of safety (RD ‐0.00, 95% CI ‐0.01 to 0.02; three studies with 606 participants; very low‐quality evidence); and tolerability as frequency of dropouts due to adverse events (3% versus 2%; RD 0.00, 95% CI ‐0.02 to 0.03; three studies with 606 participants; low‐quality evidence). </p> <p>Mirtazapine showed a clinically‐relevant benefit compared to placebo for some secondary outcomes: participant‐reported pain relief of 30% or greater (47% versus 34%; RD 0.13, 95% CI 0.05 to 0.21; number needed to treat for an additional beneficial outcome (NNTB) 8, 95% CI 5 to 20; three studies with 591 participants; low‐quality evidence); participant‐reported mean pain intensity (SMD ‐0.29, 95% CI ‐0.46 to ‐0.13; three studies with 591 participants; low‐quality evidence); and participant‐reported sleep problems (SMD ‐0.23, 95% CI ‐0.39 to ‐0.06; three studies with 573 participants; low‐quality evidence). There was no benefit for improvement of participant‐reported improvement of HRQoL of 20% or greater (58% versus 50%; RD 0.08, 95% CI ‐0.01 to 0.16; three studies with 586 participants; low‐quality evidence); participant‐reported fatigue (SMD ‐0.02, 95% CI ‐0.19 to 0.16; two studies with 533 participants; low‐quality evidence); participant‐reported negative mood (SMD ‐0.67, 95% CI ‐1.44 to 0.10; three studies with 588 participants; low‐quality evidence); or withdrawals due to lack of efficacy (1.5% versus 0.1%; RD 0.01, 95% CI ‐0.01 to 0.02; three studies with 605 participants; very low‐quality evidence). </p> <p>There was no difference between mirtazapine and placebo for participants reporting any adverse event (76% versus 59%; RD 0.12, 95 CI ‐0.01 to 0.26; three studies with 606 participants; low‐quality evidence). There was a clinically‐relevant harm with mirtazapine compared to placebo: in the number of participants with somnolence (42% versus 14%; RD 0.24, 95% CI 0.18 to 0.30; number needed to treat for an additional harmful outcome (NNTH) 5, 95% CI 3 to 6; three studies with 606 participants; low‐quality evidence); weight gain (19% versus 1%; RD 0.17, 95% CI 0.11 to 0.23; NNTH 6, 95% CI 5 to 10; three studies with 606 participants; low‐quality evidence); and elevated alanine aminotransferase (13% versus 2%; RD 0.13, 95% CI 0.04 to 0.22; NNTH 8, 95% CI 5 to 25; two studies with 566 participants; low‐quality evidence). </p> </section> <section id="CD012708-sec-0007"> <h3 class="title" id="CD012708-sec-0007">Authors' conclusions</h3> <p>Studies demonstrated no benefit of mirtazapine over placebo for pain relief of 50% or greater, PGIC, improvement of HRQoL of 20% or greater, or reduction of fatigue or negative mood. Clinically‐relevant benefits were shown for pain relief of 30% or greater, reduction of mean pain intensity, and sleep problems. Somnolence, weight gain, and elevated alanine aminotransferase were more frequent with mirtazapine than placebo. The quality of evidence was low or very low, with two of three studies of questionable quality and issues over indirectness and risk of publication bias. On balance, any potential benefits of mirtazapine in fibromyalgia were outweighed by its potential harms, though, a small minority of people with fibromyalgia might experience substantial symptom relief without clinically‐relevant adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012708-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012708-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012708-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012708-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012708-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012708-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012708-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012708-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012708-abs-0002" lang="en"> <h3>Mirtazapine for treating fibromyalgia in adults</h3> <p><b>Bottom line</b> </p> <p>Mirtazapine at 15 mg to 45 mg daily is unlikely to substantially reduce pain in people with fibromyalgia. Mirtazapine can cause drowsiness, weight gain, and liver damage. A small number of people may experience some improvement (moderate pain relief, better sleep) without side effects from mirtazapine, but that cannot be predicted. The off‐label use of mirtazapine can be considered, if established treatment options have failed. </p> <p><b>Background</b> </p> <p>People with fibromyalgia often have chronic (longer than 3 months) widespread pain, and problems with sleeping, thinking, exhaustion, and poor quality of life. There is no cure for fibromyalgia. Treatments aim to improve symptoms (pain, sleep problems, fatigue) and quality of life. </p> <p>Serotonin and noradrenaline are chemicals produced by the human body and are involved in pain, sleep, and mood. Low serotonin levels have been found in people with fibromyalgia. The antidepressant, mirtazapine, increases serotonin and noradrenaline levels in the brain. </p> <p><b>Study characteristics</b> </p> <p>In July 2018 we searched for clinical trials where mirtazapine was used to treat fibromyalgia in adults. We found three studies with 606 participants. Studies were seven to 13 weeks long. They compared mirtazapine 15 mg to 45 mg daily against a fake medication (placebo). </p> <p><b>Key results</b> </p> <p>There was no difference between mirtazapine and placebo for any primary outcome: mirtazapine and placebo reduced pain by 50% in two of 10 people (low‐quality evidence). Only one single serious adverse event was available for evaluation of safety (very low‐quality evidence). Three of 10 participants with mirtazapine and two of 10 participants with placebo dropped out of the trial due to side effects (low‐quality evidence). </p> <p>Mirtazapine reduced pain by 30% or more in five out of 10 people, compared with three out of 10 with placebo (low‐quality evidence). It was also better for average pain intensity (low‐quality evidence) and sleep problems (low‐quality evidence). Mirtazapine was not better than placebo in reducing fatigue, depression, or improving health‐related quality of life (low‐quality evidence). Mirtazapine and placebo were no different in how many participants experienced a side effect (low‐quality evidence). People dropped out at the same rate with mirtazapine and placebo or because they felt the drug did not work (low‐quality evidence). For some side effects, mirtazapine was worse than placebo. This was true for drowsiness (4 out of 10 with mirtazapine, 1 out of 10 with placebo), weight gain (2 out of 10 with mirtazapine, 0 out of 10 with placebo), and high liver enzymes (1 out of 10 with mirtazapine, 0 out of 10 with placebo) (low‐quality evidence). </p> <p><b>Quality of the evidence</b> </p> <p>Two of the studies were of poor quality. We rated the quality of the evidence using four levels: very low, low, moderate, or high. Very low‐quality evidence means that we are very uncertain about the results. High quality evidence means that we are very confident in the results. We judged that the evidence was mostly of low‐quality, which means that while the research provides some indication of the likely effect, the true effect may be substantially different. The main issues were poor study quality, decisions about the types of people included in the studies, risk of important information not being published, and sometimes low numbers of events. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012708-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012708-sec-0083"></div> <h3 class="title" id="CD012708-sec-0084">Implications for practice</h3> <section id="CD012708-sec-0084"> <section id="CD012708-sec-0085"> <h5 class="title">For people with fibromyalgia</h5> <p>Only a minority of people may benefit from treatment with mirtazapine in terms of meaningful relief of pain and sleep problems, without clinically‐relevant side effects. The majority of people will not experience substantial relief of fibromyalgia symptoms, or will experience clinically‐relevant side effects (weight gain, somnolence, liver damage), or both. </p> </section> <section id="CD012708-sec-0086"> <h5 class="title">For physicians</h5> <p>Mirtazapine is not approved for fibromyalgia in any country. Mirtazapine is approved for depressive disorders in many countries. </p> <p>Because of the side effect profile of mirtazapine, an off‐label therapeutic trial might be considered in people who do not tolerate duloxetine or milnacipran due to gastrointestinal adverse events (nausea, vomiting). If mirtazapine is being considered for the treatment of fibromyalgia, a frank discussion between the physician and patient about the potential benefits and harms of the treatment options is important. The warnings (suicide risk, concomitant use of monoaminoxidase inhibitors, agranulocytosis) and precautions (hepatotoxicity, weight gain, increase of cholesterol/triglycerides) should be discussed (<a href="./references#CD012708-bbs2-0024" title="Food and Drug Administration. Remeron® (mirtazapine) tablets. www.fda.gov/downloads/Drugs/DrugSafety/ucm089021.pdf (accessed 23 May 2018).">FDA 2017</a>). It is important to define realistic goals of treatment (e.g. pain relief of 30% or more or improvement of daily functioning, or both; <a href="./references#CD012708-bbs2-0079" title="PetzkeF , BrückleW , EidmannU , HeldmannP , KöllnerV , KühnT , et al. General principles and coordination of care and patient education in fibromyalgia syndrome. Updated guideline 2017 and review of systematic reviews [Allgemeine Behandlungsgrundsätze, Versorgungskoordination und Patientenschulung beim Fibromyalgiesyndrom: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten]. Schmerz2017;31(3):246-54. [DOI: 10.1007/s00482-017-0201-6]">Petzke 2017</a>). </p> <p>The optimal treatment dosage of mirtazapine remains to be determined. A dose response has not yet been demonstrated. Higher doses were associated with more weight gain in one study (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). Therefore a starting dose of 15 mg/d at bedtime seems reasonable. It is mandatory to continue treatment for responders only, that is to say in those who reach the predefined treatment goals with a reasonable tolerability of mirtazapine (<a href="./references#CD012708-bbs2-0079" title="PetzkeF , BrückleW , EidmannU , HeldmannP , KöllnerV , KühnT , et al. General principles and coordination of care and patient education in fibromyalgia syndrome. Updated guideline 2017 and review of systematic reviews [Allgemeine Behandlungsgrundsätze, Versorgungskoordination und Patientenschulung beim Fibromyalgiesyndrom: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten]. Schmerz2017;31(3):246-54. [DOI: 10.1007/s00482-017-0201-6]">Petzke 2017</a>). </p> <p>Therapy of fibromyalgia with drugs only is discouraged since current best practices in fibromyalgia guidelines recommend using the combination of pharmacological therapy with aerobic exercise and psychological therapies (<a href="./references#CD012708-bbs2-0052" title="MacfarlaneGJ , KronischC , DeanLE , AtzeniF , HäuserW , FlußE , et al. EULAR revised recommendations for the management of fibromyalgia. Annals of Rheumatic Diseases2017;76(2):318-28. [DOI: 10.1136/annrheumdis-2016-209724]">Macfarlane 2017</a>; <a href="./references#CD012708-bbs2-0079" title="PetzkeF , BrückleW , EidmannU , HeldmannP , KöllnerV , KühnT , et al. General principles and coordination of care and patient education in fibromyalgia syndrome. Updated guideline 2017 and review of systematic reviews [Allgemeine Behandlungsgrundsätze, Versorgungskoordination und Patientenschulung beim Fibromyalgiesyndrom: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten]. Schmerz2017;31(3):246-54. [DOI: 10.1007/s00482-017-0201-6]">Petzke 2017</a>). This is especially true for symptoms where mirtazapine is ineffective, but other therapies are effective, e.g. aerobic exercise for fatigue (<a href="./references#CD012708-bbs2-0011" title="BidondeJ , BuschAJ , SchachterCL , OverendTJ , KimSY , GóesSM , et al. Aerobic exercise training for adults with fibromyalgia. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD012700. [DOI: 10.1002/14651858.CD012700]">Bidonde 2017</a>), and cognitive‐behavioral therapies for depression (<a href="./references#CD012708-bbs2-0010" title="BernardyK , KloseP , WelschP , HäuserW . Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome - A systematic review and meta-analysis of randomized controlled trials. European Journal of Pain2018;22:242-60. [DOI: 10.1002/ejp.1121]">Bernardy 2018</a>). </p> <p>Since few participants achieve a worthwhile response with mirtazapine, it is important to establish stopping rules, so that when someone does not respond within a specified time, they can be switched to an alternative treatment. This will reduce the number of participants exposed to adverse events in the absence of benefit. </p> </section> <section id="CD012708-sec-0087"> <h5 class="title">For policy‐makers</h5> <p>Since no single treatment is effective in a majority of individuals with fibromyalgia, the relatively small number who benefit may be considered worthwhile, particularly if a) established treatment options have failed, b) appropriate switching or stopping rules are in place, and c) prescribing is under the control of physicians experienced in treating people with fibromyalgia. </p> </section> <section id="CD012708-sec-0088"> <h5 class="title">For funders</h5> <p>Treatment with mirtazapine for fibromyalgia may be considered worthwhile, particularly if a) established treatment options have failed, and b) switching and stopping rules are in place in case the predefined treatment goals are not reached or the drug is not well‐tolerated, or both. Treatment should be supervised by a physician experienced in the use of mirtazapine. </p> </section> </section> <h3 class="title" id="CD012708-sec-0089">Implications for research</h3> <section id="CD012708-sec-0089"> <section id="CD012708-sec-0090"> <h5 class="title">General</h5> <p>Analysis of all studies investigating mirtazapine in fibromyalgia at the level of individual patient data could provide important information, e.g. whether or not a clinically important pain response delivers large functional and quality of life benefits. Moreover, a reanalysis of the data using baseline observation carried forward, and responder analysis where discontinuation is classified as nonresponse, would allow a determination of the true efficacy of mirtazapine in fibromyalgia. All journals should follow the rules of the <i>BMJ</i> that reports that randomised trials will only be considered for publication if the authors commit to making the relevant anonymous patient level data available on reasonable request (<a href="./references#CD012708-bbs2-0030" title="GodleeF , GrovesT . The new BMJ policy on sharing data from drug and device trials. BMJ2012;355:e7888. [PMID: 23169872]">Godlee 2012</a>). </p> <p>Studies in any continent with the inclusion of people with inflammatory rheumatic diseases, osteoarthritis and mental disorders (depressive and anxiety disorders, post‐traumatic stress disorder) are necessary to provide external validity of the study findings. </p> <p>A standardised psychiatric interview at study entry could stratify participants according to comorbid anxiety and depressive disorders. </p> <p>Generalisability of results requires study populations that are equally recruited from every continent. </p> <p>It is mandatory that details of adverse event assessments (spontaneous reports, open question structured questions, symptom questionnaires) are reported by the studies because the type and frequency of adverse events is influenced by modes of assessment (<a href="./references#CD012708-bbs2-0037" title="HäuserW , JungE , Erbslöh-MöllerB , GesmannM , Kühn-BeckerH , PetermannF , et al. German fibromyalgia consumer reports. Benefits and harms of fibromyalgia syndrome therapies. Schmerz2012;26(2):150-9. [DOI: 10.1007/s00482-012-1161-5]">Häuser 2012</a>). Adverse events are to be reported using the International Conference on Harmonization guidelines, and coded within organ classes using the Medical Dictionary for Regulatory Activities (MedDRA version 18.0; <a href="./references#CD012708-bbs2-0042" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Introductory Guide MedDRA Version 18.0. www.meddra.org/sites/default/files/guidance/file/intguide_18_0_english.pdf (accessed prior to 30 July 2018).">ICH 2015</a>). It is desirable that regulatory agencies standardise the assessment strategies of adverse events in RCTs. </p> <p>It is important to control for potential effects of cointerventions on outcomes.</p> </section> <section id="CD012708-sec-0091"> <h5 class="title">Measurement (endpoints)</h5> <p>We recommend the use of responder criteria for the key symptoms and functional domains of fibromyalgia, namely pain, sleep problems, fatigue, depression, health‐related quality of life (HRQoL) and physical function (disability). The following responder criteria (from baseline to end of treatment) for clinical trials have been suggested: ≥ 30% pain reduction; ≥ 10% improvement in SF (Short Form Health Survey)‐36 physical function or ≥ 10% improvement in Fibromyalgia Impact Questionnaire (FIQ) physical function; ≥ 20% improvement in two of the following domains: fatigue (FIQ tiredness), sleep (FIQ rested), depression (FIQ depression), anxiety (FIQ anxiety), or cognition (Multiple Ability Self‐Report Questionnaire (MASQ)) (<a href="./references#CD012708-bbs2-0008" title="ArnoldLM , WilliamsDA , HudsonJI , MartinSA , ClauwDJ , CroffordLJ , et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis and Rheumatism2012;64:885-94. [DOI: 10.1002/art.33360]">Arnold 2012b</a>). For HRQoL, a ≥ 20% reduction of the FIQ total score has been suggested to be clinically‐relevant (<a href="./references#CD012708-bbs2-0050" title="LucianoJV , GuallarJA , AguadoJ , López-Del-HoyoY , OlivanB , MagallónR , et al. Effectiveness of group acceptance and commitment therapy for fibromyalgia: a 6-month randomized controlled trial (EFFIGACT study). Pain2014;155:693-702. [DOI: 10.1016/j.pain.2013.12.029]">Luciano 2014</a>). </p> </section> <section id="CD012708-sec-0092"> <h5 class="title">Comparison between active treatments</h5> <p>It is important to compare mirtazapine not only with placebo, but also with drugs of known efficacy, such as amitriptyline or pregabalin. In addition, more studies with defined subgroups (e.g. major depression; no adequate response to a specific drug treatment) are necessary. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012708-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012708-sec-0008"></div> <div class="table" id="CD012708-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mirtazapine compared with placebo for adult participants with fibromyalgia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Mirtazapine compared with placebo for adult participants with fibromyalgia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adult participants with fibromyalgia </p> <p><b>Settings:</b> study centres </p> <p><b>Intervention:</b> mirtazapine 15 mg/d to 45 mg/d </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> <p><b>(study duration of 7 to 13 weeks)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Probable outcome with mirtazapine<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Probable outcome with placebo (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 50% or greater (substantial improvement)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>218 (200 to 236) per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 (145 to 171) per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.05</p> <p>(‐0.01 to 0.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB not calculated due to lack of statistically significant difference between mirtazapine and placebo </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety: serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 event in 334 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 event ins 271 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.00</p> <p>(‐0.01 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>606</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meaningful calculations not possible with a single event</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolerability: withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 (30 to 39) per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 (20 to 24) per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.01</p> <p>(‐0.02 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>606</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB not calculated due to lack of statistically significant difference between mirtazapine and placebo </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 30% or greater (moderate improvement)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>472 (434 to 510) per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>336 (309 to 363) per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.13 (0.05 to 0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB was 8 (95% CI 5 to 20). Only 149 extra participants in trials of zero treatment effect to move NNTB for pain relief of 30% or greater from 8 to limit for clinical utility of 10 (25% of total number available) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported sleep problems</p> <p>(scale: 0 to 28; higher scores indicate more sleep problems)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean sleep problems<br/>score was 4.9 points<br/>lower (1.3 to<br/>8.3 points lower) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean score 11.4 (SD 5.9)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.23</p> <p>(‐0.39 to ‐0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>573</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 10 (95% CI 7 to 12)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Somnolence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>423 (389 to 457) per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 (125 to 147) per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.24 (0.18 to 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>606</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 5 (95% CI 3 to 6)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 (180 to 200) per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000 (not calculated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.17</p> <p>(0.11 to 0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>606</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 6 (95% 5 to 9)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional benefit; <b>NNTH:</b> number needed to treat for an additional harm; <b>PGIC:</b> Patient Global Impression of Change; <b>RD:</b> risk difference;<b>SMD</b>: standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p>High quality: we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p>Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> <p>Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p>Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice for indirectness (participants with inflammatory rheumatic diseases and depressive disorders excluded in &gt; 50% of studies) and risk of publication bias.<br/><sup>b</sup>Downgraded three times for imprecision due to low event rate, indirectness, and risk of publication bias.<br/><sup>c</sup>From <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>; N = 422 participants; Japanese version of the Insomnia severity index. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012708-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012708-sec-0009"></div> <p>This review is based on a template for reviews of drugs used to relieve fibromyalgia. The aim is for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD012708-bbs2-0060" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>; <a href="./appendices#CD012708-sec-0096">Appendix 1</a>). </p> <section id="CD012708-sec-0010"> <h3 class="title" id="CD012708-sec-0010">Description of the condition</h3> <p>Fibromyalgia has been defined as widespread pain that lasts for longer than three months, with pain on palpation at 11 or more of 18 specified tender points (<a href="./references#CD012708-bbs2-0094" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis and Rheumatism1990;33(2):160-72. [DOI: 10.1002/art.1780330203]">Wolfe 1990</a>). It is frequently associated with other symptoms, such as poor sleep, fatigue, and depression (<a href="./references#CD012708-bbs2-0040" title="HäuserW , AblinJ , FitzcharlesMA , LittlejohnJ , LucianoJV . Fibromyalgia. Nature Reviews Disease Primers2015;2:15022. [DOI: 10.1038/nrdp.2015.22]">Häuser 2015a</a>; <a href="./references#CD012708-bbs2-0100" title="WolfeF , WalittBT , HäuserW . What is fibromyalgia, how is it diagnosed and what does it really mean?Arthritis Care and Research2014;66(7):969-71. [DOI: 10.1002/acr.22207]">Wolfe 2014</a>). Fibromyalgia symptoms can be assessed by self‐report of the patient via the fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the American College of Rheumatology (ACR) preliminary diagnostic criteria for fibromyalgia (the Fibromyalgia Symptom Questionnaire) (<a href="./references#CD012708-bbs2-0096" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , HäuserW , KatzRS , et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. Journal of Rheumatology2011;38(6):1113-22. [DOI: 10.3899/jrheum.100594]">Wolfe 2011a</a>). For a clinical diagnosis, the ACR 1990 classification criteria (<a href="./references#CD012708-bbs2-0094" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis and Rheumatism1990;33(2):160-72. [DOI: 10.1002/art.1780330203]">Wolfe 1990</a>), the ACR 2010 preliminary diagnostic criteria (<a href="./references#CD012708-bbs2-0095" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research2010;62(5):600-10. [DOI: 10.1002/acr.20140]">Wolfe 2010</a>), and the 2016 criteria can be used (<a href="./references#CD012708-bbs2-0101" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , HäuserW , KatzRL , et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism2016;46(3):319-29. [DOI: 10.1016/j.semarthrit.2016.08.012]">Wolfe 2016</a>). Lacking a specific laboratory test, diagnosis is established by a history of the key symptoms and the exclusion of somatic diseases sufficiently explaining the key symptoms (<a href="./references#CD012708-bbs2-0040" title="HäuserW , AblinJ , FitzcharlesMA , LittlejohnJ , LucianoJV . Fibromyalgia. Nature Reviews Disease Primers2015;2:15022. [DOI: 10.1038/nrdp.2015.22]">Häuser 2015a</a>). </p> <p>Fibromyalgia is a heterogenous condition. The definite aetiology (cause) of this syndrome remains unknown. A model of interacting biological and psychosocial variables in the predisposition, triggering, and development of the chronicity of fibromyalgia symptoms has been suggested (<a href="./references#CD012708-bbs2-0103" title="ÜçeylerN , BurgmerM , FriedelE , GreinerW , PetzkeF , SarholzM , et al. Etiology and pathophysiology of fibromyalgia syndrome: Updated guideline 2017, overview of systematic reviews and review of studies on small fiber pathology in subgroups of fibromyalgia syndrome [Ätiologie und Pathophysiologie des Fibromyalgiesyndroms: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten sowie eine Übersicht über Studien zur Kleinfaserpathologie bei Subgruppen des FMS]. Schmerz2017;31(3):239-45. [DOI: 10.1007/s00482-017-0202-5]">Üceyler 2017</a>). Genetics (<a href="./references#CD012708-bbs2-0007" title="ArnoldLM , FanJ , RussellIJ , YunusMB , KhanMA , KushnerI , et al. The fibromyalgia family study: a genome wide linkage scan study. Arthritis and Rheumatism2013;65:1122-8. [DOI: 10.1002/art.37842]">Arnold 2012a</a>; <a href="./references#CD012708-bbs2-0048" title="LeeYH , ChoiSJ , JiJD , SongGG . Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatology International2012;32(2):417-26. [DOI: DOI: 10.1007/s00296-010-1678-9]">Lee 2012</a>), depression (<a href="./references#CD012708-bbs2-0012" title="ChangMH , HsuJW , HuangKL , SuTP , BaiYM , LiCT , et al. Bidirectional association between depression and fibromyalgia syndrome: a nationwide longitudinal study. Journal of Pain2015;16:895-902. [DOI: 10.1016/j.jpain.2015.06.004]">Chang 2014</a>; <a href="./references#CD012708-bbs2-0026" title="ForsethKO , HusbyG , GranJT , FørreO . Prognostic factors for the development of fibromyalgia in women with self reported musculoskeletal pain. Journal of Rheumatology1999;26:2458–67. [PMID: 10555910]">Forseth 1999</a>), physical and sexual abuse in childhood (<a href="./references#CD012708-bbs2-0036" title="HäuserW , KossevaM , ÜceylerN , KloseP , SommerC . Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis. Arthritis Care and Research2011;63:808-20. [DOI: 10.1002/acr.20328]">Häuser 2011</a>), obesity combined with physical inactivity (<a href="./references#CD012708-bbs2-0072" title="MorkPJ , VasseljenO , NilsenTI . Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study. Arthritis Care and Research2010;62(5):611-7. [DOI: 10.1002/acr.20118]">Mork 2010</a>), sleep problems (<a href="./references#CD012708-bbs2-0073" title="MorkPG , NilsenTI . Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis and Rheumatism2012;64(1):281-4. [DOI: 10.1002/art.33346]">Mork 2012</a>), and smoking (<a href="./references#CD012708-bbs2-0013" title="ChoiCJ , KnutsenR , OdaK , FraserGE , KnutsenS . The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study. Journal of Pain2011;11:994-1103. [DOI: 10.1016/j.jpain.2010.01.267]">Choi 2011</a>), might predispose a person to the development of fibromyalgia. Inflammatory rheumatic diseases (<a href="./references#CD012708-bbs2-0049" title="LeeYC , LuB , BoireG , HaraouiB , HitchonCA , PopeJE , et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Annals of Rheumatic Diseases2013;72(6):949–54. [DOI: 10.1136/annrheumdis-2012-201506]">Lee 2013</a>; <a href="./references#CD012708-bbs2-0097" title="WolfeF , HäuserW , HassettAL , KatzRS , WalittBT . The development of fibromyalgia - I: Examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain2011;152(2):291-9. [DOI: 10.1016/j.pain.2010.09.027]">Wolfe 2011b</a>), psychosocial stress (e.g. workplace and family conflicts) and physical stress (e.g. infections, surgery, accidents) might trigger the onset of chronic widespread pain and fatigue (<a href="./references#CD012708-bbs2-0016" title="ClauwD . Fibromyalgia: a clinical review. JAMA2014;311:1547-55. [DOI: 10.1001/jama.2014.3266]">Clauw 2014</a>). Depression and post‐traumatic stress disorder worsen fibromyalgia symptoms (<a href="./references#CD012708-bbs2-0039" title="HäuserW , GalekA , Erbslöh-MöllerB , KöllnerV , Kühn-BeckerH , LanghorstJ , et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain2013;154(8):1216-23. [DOI: 10.1016/j.pain.2013.03.034]">Häuser 2013b</a>; <a href="./references#CD012708-bbs2-0046" title="LangeM , PetermannF . Influence of depression on fibromyalgia: a systematic review. Schmerz2010;24(4):326-33. [DOI: 10.1007/s00482-010-0937-8]">Lange 2010</a>). </p> <p>Several factors are associated with the pathophysiology (functional changes associated with or resulting from disease) of fibromyalgia, but the precise relationship to symptoms of the disorder are unclear (<a href="./references#CD012708-bbs2-0103" title="ÜçeylerN , BurgmerM , FriedelE , GreinerW , PetzkeF , SarholzM , et al. Etiology and pathophysiology of fibromyalgia syndrome: Updated guideline 2017, overview of systematic reviews and review of studies on small fiber pathology in subgroups of fibromyalgia syndrome [Ätiologie und Pathophysiologie des Fibromyalgiesyndroms: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten sowie eine Übersicht über Studien zur Kleinfaserpathologie bei Subgruppen des FMS]. Schmerz2017;31(3):239-45. [DOI: 10.1007/s00482-017-0202-5]">Üceyler 2017</a>). The best established pathophysiological features are those of central sensitisation; i.e. augmented pain and sensory processing in the brain, with increased functional connectivity to pronociceptive brain regions and decreased connectivity to antinociceptive regions, and accompanying changes in central nervous system (CNS) neurotransmitters, as well as the size and shape of brain regions (<a href="./references#CD012708-bbs2-0016" title="ClauwD . Fibromyalgia: a clinical review. JAMA2014;311:1547-55. [DOI: 10.1001/jama.2014.3266]">Clauw 2014</a>). Other findings include sympathetic nervous system dysfunction (<a href="./references#CD012708-bbs2-0053" title="Martínez-MartínezLA , MoraT , VargasA , Fuentes-IniestraM , Martínez-LavínM . Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case-control studies. Journal of Clinical Rheumatology2014;20(3):146-50. [DOI: 10.1097/RHU.0000000000000089]">Martínez‐Martínez 2014</a>), increased proinflammatory and reduced anti‐inflammatory cytokine profiles (produced by cells involved in inflammation) (<a href="./references#CD012708-bbs2-0102" title="ÜceylerN , HäuserW , SommerC . Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskeletal Disorders2011;12:245. [DOI: 10.1186/1471-2474-12-245]">Üceyler 2011</a>), and small fibre pathology (<a href="./references#CD012708-bbs2-0103" title="ÜçeylerN , BurgmerM , FriedelE , GreinerW , PetzkeF , SarholzM , et al. Etiology and pathophysiology of fibromyalgia syndrome: Updated guideline 2017, overview of systematic reviews and review of studies on small fiber pathology in subgroups of fibromyalgia syndrome [Ätiologie und Pathophysiologie des Fibromyalgiesyndroms: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten sowie eine Übersicht über Studien zur Kleinfaserpathologie bei Subgruppen des FMS]. Schmerz2017;31(3):239-45. [DOI: 10.1007/s00482-017-0202-5]">Üceyler 2017</a>). </p> <p>Fibromyalgia is common. Numerous studies have investigated prevalence in different settings and countries. The <a href="./references#CD012708-bbs2-0080" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):356. [DOI: 10.1007/s11916-013-0356-5]">Queiroz 2013</a> review gives a global mean prevalence of 2.7% (range 0.4% to 9.3%), and a mean in the Americas of 3.1%, in Europe of 2.5%, and in Asia of 1.7%. Fibromyalgia is more common in women, with a female to male ratio of 3:1 (4.2%:1.4%). The change in diagnostic criteria does not appear to have significantly affected estimates of prevalence (<a href="./references#CD012708-bbs2-0098" title="WolfeF , BrählerE , HinzA , HäuserW . Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care and Research2013;645(5):777-85. [DOI: 10.1002/acr.21931]">Wolfe 2013a</a>). Estimates of prevalence in specific populations vary greatly, but have been reported to be as high as 9% in female textile workers in Turkey and 10% in metal workers in Brazil (59% in those with repetitive strain injury; <a href="./references#CD012708-bbs2-0080" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):356. [DOI: 10.1007/s11916-013-0356-5]">Queiroz 2013</a>). </p> <p>People with fibromyalgia often report high disability levels and poor quality of life, along with extensive use of medical care (<a href="./references#CD012708-bbs2-0040" title="HäuserW , AblinJ , FitzcharlesMA , LittlejohnJ , LucianoJV . Fibromyalgia. Nature Reviews Disease Primers2015;2:15022. [DOI: 10.1038/nrdp.2015.22]">Häuser 2015a</a>). Many people with fibromyalgia are significantly disabled, and experience moderate or severe pain for many years (<a href="./references#CD012708-bbs2-0009" title="BennettRM , JonesJ , TurkDC , RussellIJ , MatallanaL . An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders2007;8:27. [DOI: 10.1186/1471-2474-8-27]">Bennett 2007</a>). Chronic painful conditions comprised five of the 11 top‐ranking conditions for years lived with disability in 2010 (<a href="./references#CD012708-bbs2-0090" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163-96. [DOI: 10.1016/S0140-6736(12)61729-2]">Vos 2012</a>), and are responsible for considerable loss of quality of life and employment, and increased health costs (<a href="./references#CD012708-bbs2-0070" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79-94. [DOI: 10.1111/papr.12050]">Moore 2014a</a>). </p> <p>Fibromyalgia pain is known to be difficult to treat effectively, with only a minority of individuals experiencing a clinically‐relevant benefit from any one intervention. A multidisciplinary approach is now advocated, combining pharmacological interventions with physical or cognitive interventions, or both. Interventions aim to reduce the key symptoms of fibromyalgia (pain, sleep problems, fatigue) and the associated symptoms (e.g. depression, disability) and to improve daily functioning (<a href="./references#CD012708-bbs2-0025" title="FitzcharlesMA , Ste-MariePA , GoldenbergDL , PereiraJX , AbbeyS , ChoinièreM , et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Research and Management2013;18:119-26. [DOI: 10.1155/2013/918216]">Fitzcharles 2012</a>; <a href="./references#CD012708-bbs2-0052" title="MacfarlaneGJ , KronischC , DeanLE , AtzeniF , HäuserW , FlußE , et al. EULAR revised recommendations for the management of fibromyalgia. Annals of Rheumatic Diseases2017;76(2):318-28. [DOI: 10.1136/annrheumdis-2016-209724]">Macfarlane 2017</a>; <a href="./references#CD012708-bbs2-0079" title="PetzkeF , BrückleW , EidmannU , HeldmannP , KöllnerV , KühnT , et al. General principles and coordination of care and patient education in fibromyalgia syndrome. Updated guideline 2017 and review of systematic reviews [Allgemeine Behandlungsgrundsätze, Versorgungskoordination und Patientenschulung beim Fibromyalgiesyndrom: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten]. Schmerz2017;31(3):246-54. [DOI: 10.1007/s00482-017-0201-6]">Petzke 2017</a>). Conventional analgesics are usually not effective. Treatment is often by so‐called pain modulators, such as antidepressants like duloxetine and amitriptyline (<a href="./references#CD012708-bbs2-0038" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD010292. [DOI: 10.1002/14651858.CD010292]">Häuser 2013a</a>; <a href="./references#CD012708-bbs2-0051" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD007115. [DOI: 10.1002/14651858.CD007115.pub3]">Lunn 2014</a>; <a href="./references#CD012708-bbs2-0066" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD008242. [DOI: 10.1002/14651858.CD008242.pub2]">Moore 2012a</a>), or antiepileptics like gabapentin or pregabalin (<a href="./references#CD012708-bbs2-0019" title="CooperTE , DerryS , WiffenPJ , MooreRA . Gabapentin for fibromyalgia pain in adults. Cochrane Database of Systematic Reviews2017, Issue 1. Art. No: CD012188. [DOI: 10.1002/14651858.CD012188.pub2]">Cooper 2017</a>; <a href="./references#CD012708-bbs2-0059" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD007076. [DOI: 10.1002/14651858.CD007076.pub2]">Moore 2009</a>; <a href="./references#CD012708-bbs2-0093" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD010567. [DOI: 10.1002/14651858.CD010567.pub2]">Wiffen 2013</a>). The proportion of people who achieve worthwhile pain relief (typically at least a 50% reduction in pain intensity; <a href="./references#CD012708-bbs2-0068" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12. [DOI: 10.1111/anae.12148]">Moore 2013a</a>) is small, generally only 10% to 15% more than with placebo, with number needed to treat for an additional beneficial outcome (NNTB) usually between 6 and 14 (<a href="./references#CD012708-bbs2-0093" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD010567. [DOI: 10.1002/14651858.CD010567.pub2]">Wiffen 2013</a>). Those who do experience good levels of pain relief with pregabalin also benefit from substantial improvements in other symptoms, such as fatigue, function, sleep, depression, anxiety, and ability to work, with significant improvement in quality of life (<a href="./references#CD012708-bbs2-0061" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]">Moore 2010b</a>; <a href="./references#CD012708-bbs2-0070" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79-94. [DOI: 10.1111/papr.12050]">Moore 2014a</a>). Fibromyalgia is not particularly different from other chronic pain in that only a small proportion of trial participants have a good response to treatment (<a href="./references#CD012708-bbs2-0069" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690]">Moore 2013b</a>). </p> </section> <section id="CD012708-sec-0011"> <h3 class="title" id="CD012708-sec-0011">Description of the intervention</h3> <p>Mirtazapine is an atypical antidepressant with noradrenergic and specific serotonergic activity. It is licensed for use in major depressive disorders, but not in fibromyalgia. It is also used off‐label for a variety of other disorders, including anxiety‐related disorders and insomnia. Mirtazapine is administered orally, preferably once a day at bedtime. The recommended dosages for the treatment of depression range between 15 mg/d and 45 mg/d. </p> <p>Mirtazapine is regarded to be a well‐tolerated and safe antidepressant. Studies have demonstrated a significantly lower percentage of participants reporting any adverse clinical experiences with mirtazapine (65%) when compared with placebo (76%) or amitriptyline (87%) (<a href="./references#CD012708-bbs2-0056" title="MontgomerySA . Safety of mirtazapine: a review. International Clinical Psychopharmacology1995;10 Suppl 4:37-45. [PMID: 8930008]">Montgomery 1995</a>). Moreover, dropout rates due to adverse clinical experiences were significantly lower than in the amitriptyline treatment group. Data show there are few cardiotoxic properties when used in participants with heart failure (<a href="./references#CD012708-bbs2-0056" title="MontgomerySA . Safety of mirtazapine: a review. International Clinical Psychopharmacology1995;10 Suppl 4:37-45. [PMID: 8930008]">Montgomery 1995</a>). </p> </section> <section id="CD012708-sec-0012"> <h3 class="title" id="CD012708-sec-0012">How the intervention might work</h3> <p>Mirtazapine blocks the alpha 2 adrenergic auto‐ and heteroreceptors (enhancing noradrenaline release), and selectively antagonises the 5‐hydroxytryptamine receptor 2 (5‐HT2) serotonin receptors in the central and peripheral nervous system. It also enhances serotonin neurotransmission at the 5‐HT1 receptor 1 and blocks the histaminergic and muscarinic receptors. Mirtazapine is not a serotonin norepinephrine reuptake inhibitor but increases serotonin and noradrenaline by other mechanisms of action (<a href="./references#CD012708-bbs2-0044" title="KentJM . SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet2000;355(9219):911-8. [DOI: 10.1016/S0140-6736(99)11381-3]">Kent 2000</a>). Based on these pharmacological mechanisms, mirtazapine is classified as a noradrenergic and specific serotonergic antidepressant. In structure, mirtazapine can also be classified as a tetracyclic antidepressant (<a href="./references#CD012708-bbs2-0005" title="AnttilaSAK , LeinonenEVJ . A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Review2000;7:249-64. [DOI: 10.1111/j.1527-3458.2001.tb00198.x]">Antilla 2000</a>). Based on its pharmacologic profile, mirtazapine has the potential to be beneficial in the treatment of fibromyalgia, especially in people who suffer from sleep disturbances (<a href="./references#CD012708-bbs2-0021" title="DolderCR , NelsonMH , IlerCA . The effects of mirtazapine on sleep in patients with major depressive disorder. Annals of Clinical Psychiatry2012;24:215-24. [PMID: 22860241]">Dolder 2012</a>). </p> </section> <section id="CD012708-sec-0013"> <h3 class="title" id="CD012708-sec-0013">Why it is important to do this review</h3> <p>The serotonin‐norepinephrine reuptake inhibitor antidepressants, duloxetine and milnacipran, have been approved by the Food and Drug Administration (FDA), but not by the European Medicines Agency (EMA) for fibromyalgia (<a href="./references#CD012708-bbs2-0038" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD010292. [DOI: 10.1002/14651858.CD010292]">Häuser 2013a</a>). Both drugs increase the availability of serotonin 5‐HT and norepinephrine at CNS synaptic clefts. They have the potential to reduce pain by correcting the functional deficit of 5‐HT and norepinephrine neurotransmission in the descending inhibitory pain pathway. These antidepressants are effective in relieving one key symptom of fibromyalgia, namely pain, but do not reduce sleep problems to a clinically‐relevant degree (<a href="./references#CD012708-bbs2-0038" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD010292. [DOI: 10.1002/14651858.CD010292]">Häuser 2013a</a>). There is a need for additional pharmacological therapeutic options for the treatment of the key fibromyalgia symptoms of pain, sleep problems and fatigue. </p> <p>A patient survey in 2012 demonstrated that mirtazapine was rarely used by patients with fibromyalgia (<a href="./references#CD012708-bbs2-0037" title="HäuserW , JungE , Erbslöh-MöllerB , GesmannM , Kühn-BeckerH , PetermannF , et al. German fibromyalgia consumer reports. Benefits and harms of fibromyalgia syndrome therapies. Schmerz2012;26(2):150-9. [DOI: 10.1007/s00482-012-1161-5]">Häuser 2012</a>). However, uncontrolled trials suggested that mirtazapine might be effective in relieving fibromyalgia symptoms (<a href="./references#CD012708-bbs2-0083" title="SamborskiW , Lezańska-SzperaM , RybakowskiJK . Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry2004;37(4):168-70. [DOI: 10.1055/s-2004-827172]">Samborski 2004</a>). The use of mirtazapine to reduce sleep problems is discussed in fibromyalgia Internet chats (<a href="./references#CD012708-bbs2-0092" title="Fibromyalgia Community. Remerone anyone?forums.webmd.com/3/fibromyalgia-exchange/forum/3685 (accessed 2 February 2017).">WebMD Fibromyalgia Community 2009</a>). Mirtazapine increases the pain threshold in healthy adults (<a href="./references#CD012708-bbs2-0006" title="ArnoldP , VuadensP , KuntzerT , GobeletC , DeriazO . Mirtazapine decreases the pain feeling in healthy participants. Clinical Journal of Pain2008;24(2):116-9. [DOI: 10.1097/AJP.0b013e318159f94a]">Arnold 2008</a>). Moreover, a large (594 participants), open, postmarketing survey of the use of mirtazapine in people with chronic pain and concomitant depression, demonstrated that after six weeks almost 70% of participants reported light or no pain on a faces scale, compared with 90% having severe or worst pain at baseline (<a href="./references#CD012708-bbs2-0027" title="FreynhagenR , Muth-SelbachU , LipfertP , StevensMF , ZacharowskiK , TölleTR , et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Current Medical Research and Opinion2006;22(2):257-64. [DOI: 10.1185/030079906X80486]">Freynhagen 2006</a>). There is, therefore, a need to evaluate the efficacy, tolerability and safety of mirtazapine in fibromyalgia in order to assist people with fibromyalgia and doctors in shared decision making on additional pharmacological treatment options. </p> <p>The standards used to assess evidence in chronic pain trials have changed substantially, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy. The most important change is the move from using average pain scores, or average change in pain scores, to the number of people who have a large decrease in pain (by at least 50%) and who continue in treatment, ideally in trials of eight to 12 weeks or longer. Pain intensity reduction of 50% or more has been shown to correlate with improvements in comorbid symptoms, function, and quality of life for people with chronic pain (<a href="./references#CD012708-bbs2-0018" title="ConaghanPG , PelosoPM , EverettSV , RajagopalanS , BlackCM , MavrosP , et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford)2015;54(2):270-7. [DOI: 10.1093/rheumatology/keu332]">Conaghan 2015</a>; <a href="./references#CD012708-bbs2-0068" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12. [DOI: 10.1111/anae.12148]">Moore 2013a</a>; <a href="./references#CD012708-bbs2-0078" title="PelosoPM , MooreRA , ChenWJ , LinHY , GatesDF , StrausWL , et al. Osteoarthritis patients with pain improvement are highly likely to also have improved quality of life and functioning. A post hoc analysis of a clinical trial. Scandinavian Journal of Pain2016;13(10):175-81. [DOI: 10.1016/j.sjpain.2016.07.002]">Peloso 2016</a>), and specifically fibromyalgia (<a href="./references#CD012708-bbs2-0061" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]">Moore 2010b</a>; <a href="./references#CD012708-bbs2-0087" title="StraubeS , MooreRA , PaineJ , DerryS , PhillipsCJ , HallierE , et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskeletal Disorders2011;12:125. [DOI: 10.1186/1471-2474-12-125]">Straube 2011</a>). These standards are set out in the reference guide for pain reviews (<a href="./references#CD012708-bbs2-0077" title="Pain, Palliative and Supportive Care. PaPaS author and referee guidance. papas.cochrane.org/papas-documents (accessed 28 February 2017).">PaPaS 2012</a>). </p> <p>In this Cochrane Review we assessed evidence using methods that make both statistical and clinical sense, and used a developing criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD012708-bbs2-0060" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>). We required a minimum of reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc.), and requirements for clinically‐relevant benefit (number needed to treat for an additional beneficial outcome (NNTB) is less than 10); <a href="./references#CD012708-bbs2-0057" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]">Moore 1998</a>). This approach sets high standards and marks a departure from how reviews were conducted previously. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012708-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012708-sec-0014"></div> <p>To assess the efficacy, tolerability and safety of the tetracyclic antidepressant, mirtazapine, compared with placebo or other active drug(s) in the treatment of fibromyalgia in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012708-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012708-sec-0015"></div> <section id="CD012708-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012708-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with double‐blind assessment of participant outcomes following four weeks of treatment or longer. We included trials with a parallel, cross‐over, and enriched enrolment randomised withdrawal design. We did not include N‐of‐1 studies. We required full journal publication, with the exception of online clinical trial results, summaries of otherwise unpublished clinical trials, and abstracts with sufficient data for analysis. We did not include short abstracts (usually meeting reports). We excluded studies that were nonrandomised, studies of experimental pain, case reports, and clinical observations. </p> </section> <section id="CD012708-sec-0018"> <h4 class="title">Types of participants</h4> <p>Studies included adult participants aged 18 years and above, diagnosed with fibromyalgia using the American College of Rheumatology (ACR) 1990 classification criteria (<a href="./references#CD012708-bbs2-0094" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis and Rheumatism1990;33(2):160-72. [DOI: 10.1002/art.1780330203]">Wolfe 1990</a>), the ACR 2010 preliminary diagnostic criteria (<a href="./references#CD012708-bbs2-0095" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research2010;62(5):600-10. [DOI: 10.1002/acr.20140]">Wolfe 2010</a>), or the modified ACR 2010 preliminary diagnostic criteria (research criteria) (<a href="./references#CD012708-bbs2-0096" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , HäuserW , KatzRS , et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. Journal of Rheumatology2011;38(6):1113-22. [DOI: 10.3899/jrheum.100594]">Wolfe 2011a</a>). </p> </section> <section id="CD012708-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies that administered mirtazapine at any dose, by any route, for the relief of fibromyalgia symptoms, compared to placebo or any active comparator. </p> </section> <section id="CD012708-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We anticipated that studies would use a variety of outcome measures, with the majority using standard subjective scales (numerical rating scale or visual analogue scale) for pain intensity or pain relief, or both. We were particularly interested in the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (<a href="./references#CD012708-bbs2-0022" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]">Dworkin 2008</a>). </p> <p>These are defined as at least 30% pain relief over baseline (moderate), at least 50% pain relief over baseline (substantial), much or very much improved on Patient Global Impression of Change (PGIC) (moderate), and very much improved on PGIC (substantial). These dichotomous outcomes should be used where pain responses do not follow a normal (Gaussian) distribution. People with chronic pain desire high levels of pain relief, ideally more than 50%, and with pain not worse than mild (<a href="./references#CD012708-bbs2-0068" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12. [DOI: 10.1111/anae.12148]">Moore 2013a</a>; <a href="./references#CD012708-bbs2-0076" title="O'BrienEM , StaudRM , HassingerAD , McCullochRC , CraggsJG , AtchisonJW , et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x]">O'Brien 2010</a>). </p> <section id="CD012708-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012708-list-0001"> <li> <p>Participant‐reported pain relief of 50% or greater (substantial improvement).</p> </li> <li> <p>PGIC very much improved (substantial improvement).</p> </li> <li> <p>Safety: participants experiencing any serious adverse event. Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an 'important medical event' that may jeopardise the person, or may require an intervention to prevent one of the above characteristics or consequences. </p> </li> <li> <p>Tolerability: withdrawals due to adverse events.</p> </li> </ul> </p> </section> <section id="CD012708-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012708-list-0002"> <li> <p>Participant‐reported pain relief of 30% or greater (moderate improvement).</p> </li> <li> <p>PGIC much improved (moderate improvement).</p> </li> <li> <p>Participant‐reported sleep problems (continuous outcome: we preferred composite measures over single item scales). </p> </li> <li> <p>Participant‐reported fatigue (continuous outcome: we preferred composite measures over single item scales). </p> </li> <li> <p>Participant‐reported mean pain intensity (continuous outcome: we preferred change from baseline scores over intensity at the end of the study). </p> </li> <li> <p>Participant‐reported improvement of health‐related quality of life (HRQoL): we preferred disease‐specific instruments such as the Fibromyalgia Impact Questionnaire (FIQ) over generic instruments. If FIQ scores were reported we calculated the number of participants with a clinically‐relevant improvement of 20% or greater. </p> </li> <li> <p>Participant‐reported negative mood (continuous outcome: we preferred composite measures such as the Beck Depression Inventory (BDI) or the Hospital Anxiety and Depression (HAD) scale over single item scales). </p> </li> <li> <p>Withdrawals due to lack of efficacy.</p> </li> <li> <p>Participants reporting any adverse event.</p> </li> <li> <p>Participants with specific adverse events: somnolence; substantial weight gain; elevated alanine aminotransferase (liver enzymes) are examples. </p> </li> </ul> </p> </section> </section> </section> <section id="CD012708-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012708-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases from inception and without language restrictions.</p> <p> <ul id="CD012708-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL via Cochrane Register of Studies Online) on 9 July 2018. </p> </li> <li> <p>MEDLINE (via Ovid) from 1947 to 9 July 2018.</p> </li> <li> <p>Embase (via Ovid), from 1974 to 9 July 2018.</p> </li> <li> <p>Scopus (via Ovid) from 1974 to 9 July 2018.</p> </li> </ul> </p> <p>The search strategies for CENTRAL, MEDLINE, Embase, SCOPUS, and other databases are shown in <a href="./appendices#CD012708-sec-0097">Appendix 2</a>, <a href="./appendices#CD012708-sec-0098">Appendix 3</a>, <a href="./appendices#CD012708-sec-0099">Appendix 4</a>, <a href="./appendices#CD012708-sec-0100">Appendix 5</a>, and <a href="./appendices#CD012708-sec-0101">Appendix 6</a>, respectively. </p> </section> <section id="CD012708-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We reviewed the bibliographies of any RCTs and review articles identified. We searched the following clinical trial databases to identify additional published or unpublished data: US National Insitutes of Health (<a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>), and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). We contacted investigators and study sponsors for additional information. </p> </section> </section> <section id="CD012708-sec-0026"> <h3 class="title" id="CD012708-sec-0026">Data collection and analysis</h3> <section id="CD012708-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy the inclusion criteria, and obtained full copies of the remaining studies. Two review authors (WH, PW) made the decisions. Two review authors (WH, PW) then read these studies independently and reached agreement about inclusion by discussion. We did not anonymise the studies in any way before assessment. We created a PRISMA flow chart (<a href="./references#CD012708-bbs2-0055" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Medicine2009;6:e1000097. [DOI: 10.1371/journal.pmed1000097 ]">Moher 2009</a>). </p> </section> <section id="CD012708-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (WH, RAM) extracted data independently using a standard form and checked for agreement before entry into Review Manager 5 (<a href="./references#CD012708-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We extracted information about the study setting, demographic and clinical variables of the participants, number of participants treated, drug and dosing regimen, comedication, study design (placebo or active control; parallel, cross‐over, or enriched enrolment randomised withdrawal), study duration and follow‐up, outcome measures and results, withdrawals and adverse events (participants experiencing any adverse event, or serious adverse event). </p> </section> <section id="CD012708-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Oxford Quality Score as the basis for inclusion (<a href="./references#CD012708-bbs2-0043" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Controlled Clinical Trials1996;17(1):1-12. [DOI: org/10.1016/0197-2456(95)00134-4]">Jadad 1996</a>), limiting inclusion to studies that were randomised and double‐blind as a minimum. </p> <p>Two review authors (WH, RAM) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012708-bbs2-0034" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), and adapted from those used by Cochrane Pregnancy and Childbirth, with any disagreements resolved by discussion. We assessed the following for each study. </p> <p> <ul id="CD012708-list-0004"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (i.e. any truly random process, for example, random number table; computer random number generator) or unclear risk of bias (when the method used to generate the sequence was not clearly stated). We excluded studies at a high risk of bias that use a nonrandom process (for example, odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (for example, telephone or central randomisation; consecutively numbered, sealed, opaque envelopes) or unclear risk of bias (when method not clearly stated). We excluded studies that did not conceal allocation and were therefore at a high risk of bias (for example, open list). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (e.g. study stated that it was blinded and described the method used to achieve blinding, for example, identical tablets, matched in appearance and smell) or unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We excluded studies at a high risk of bias where participants and study personnel were not blinded. </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that outcome assessor was not involved in treatment); unclear risk of bias (study stated that the assessor was blinded but did not provide an adequate description of how it was achieved); high risk of bias (outcome assessors not blinded to treatment). </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (i.e. less than 10% of participants did not complete the study or used 'baseline observation carried forward' analysis, or both); unclear risk of bias (used 'last observation carried forward' analysis); or high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Reporting bias due to selective outcome reporting (reporting bias). We checked if an a priori study protocol was available and if all outcomes of the study protocol were reported in the publications of the study. We assessed the methods used to deal with incomplete data as: low risk of reporting bias if the study protocol was available and all of the study's prespecified (primary and secondary) outcomes that were of interest in the review were reported in the prespecified way, or if the study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon); high risk of reporting bias if not all of the study's prespecified primary outcomes were reported; one or more primary outcomes was reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected adverse effect); one or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis; the study report did not include results for a key outcome that would be expected to have been reported for such a study. We assessed the methods as unclear risk of bias if insufficient information was available to permit judgement of ‘low risk’ or ‘high risk’. </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (when there were 200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of bias (fewer than 50 participants per treatment arm). </p> </li> <li> <p>Group similarity at baseline (selection bias). We assessed similarity of the study groups at baseline for the most important prognostic clinical and demographic indicators. We assigned a low risk of bias if groups were similar at baseline for demographic factors, value of main outcome measure(s) and important prognostic factors. We assigned an unclear risk of bias if important prognostic clinical and demographic indicators were not reported, and a high risk of bias if groups were not similar at baseline for demographic factors, value of main outcome measure(s), and important prognostic factor. </p> </li> </ul> </p> <p>Two review authors (WH, PW) made quality ratings separately for each of the eight methodology quality indicators as defined by the 'Risk of bias' tool. We defined a study to be of high quality if six to eight of the domains were at low risk of bias, to be of moderate quality if three to five of eight domains were at low risk of bias, and to be of low quality if zero to two of eight domains were at low risk of bias (<a href="./references#CD012708-bbs2-0084" title="SchaefertR , WelschP , KloseP , SommerC , PetzkeF , HäuserW . Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz2015;29(1):47-59. [DOI: 10.1007/s00482-014-1451-1]">Schaefert 2015</a>). </p> </section> <section id="CD012708-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated number needed to treat for an additional beneficial outcome (NNTB) as the reciprocal of the absolute risk reduction (ARR; <a href="./references#CD012708-bbs2-0054" title="McQuayHJ , MooreRA . An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998.">McQuay 1998</a>). For unwanted effects, the NNTB becomes the number needed to treat for an additional harmful outcome (NNTH) and is calculated in the same manner. </p> <p>We used the following terms to describe adverse outcomes in terms of harm or prevention of harm. </p> <p> <ul id="CD012708-list-0005"> <li> <p>When significantly fewer adverse outcomes occurred with treatment than with control (placebo or active), we used the term: 'number needed to treat to prevent one event (NNTp)'. </p> </li> <li> <p>When significantly more adverse outcomes occurred with treatment compared with control (placebo or active), we used the term: 'number needed to treat for an additional harmful outcome (NNTH)'. </p> </li> </ul> </p> <p>In the event we judged there to be clinical heterogeneity between the studies, and so we used a random‐effects analysis throughout. </p> <p>For dichotomous data we calculated risk differences (RDs) (inverse variance method) with 95% confidence intervals (CIs) using a random‐effects model (see below). We set the threshold for a clinically‐relevant benefit for categorical variables as a NNTB of less than 10 (<a href="./references#CD012708-bbs2-0058" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978–0–931092–69–5]">Moore 2008</a>). </p> <p>For continuous data we calculated standardised mean differences (SMDs) with 95% CIs using a random‐effects model. We used Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD, with Hedges' g of 0.2 = small, 0.5 = medium and 0.8 = large (<a href="./references#CD012708-bbs2-0017" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. Erlbaum, 1988. [ISBN 9780805802832]">Cohen 1988</a>). We considered g &lt; 0.2 to be a 'not substantial' effect size. We assumed a minimally important difference if Hedges' g was ≥ 0.2 (<a href="./references#CD012708-bbs2-0023" title="FayersPM , HaysRD . Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Quality of Life Research2014;23:1-4. [DOI: 10.1007/s11136-013-0443-4]">Fayers 2014</a>). We calculated the NNTB for continuous variables (sleep problems, fatigue) using the Wells calculator software available at Cochrane Musculoskeletal editorial office, which estimates from SMDs the proportion of participants who benefit from treatment. We used a minimal clinically important difference of 20% for the calculation of NNTB from SMDs for continuous outcomes. </p> </section> <section id="CD012708-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We split the control treatment arm between active treatment arms in a single study if the active treatment arms were not combined for analysis. </p> </section> <section id="CD012708-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We used intention‐to‐treat (ITT) analysis where the ITT population consists of participants who were randomised, took at least one dose of the assigned study medication, and provided at least one postbaseline assessment. We assigned missing participants zero improvement wherever possible. Where standard deviations (SDs) were not reported, we calculated them from P values, CIs or standard errors, where reported in articles (<a href="./references#CD012708-bbs2-0034" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). Where 30% and 50% pain relief rates and 20% Fibromyalgia Impact Questionnaire (FIQ) improvement rates were not reported and not provided on request, we calculated them from means and SDs by a validated imputation method (<a href="./references#CD012708-bbs2-0029" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology2005;20:49-52. [PMID: 15602117]">Furukawa 2005</a>). </p> </section> <section id="CD012708-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We dealt with clinical heterogeneity by combining studies that examined similar conditions. We assessed statistical heterogeneity visually (<a href="./references#CD012708-bbs2-0045" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta-analysis in clinical research. Annals of Internal Medicine1987;107(2):224-33. [DOI: 10.7326/0003-4819-107-2-224]">L'Abbé 1987</a>), and with the use of the I² statistic. When the I² value was greater than 50%, we considered possible reasons for this. </p> </section> <section id="CD012708-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We aimed to use dichotomous outcomes of known utility and of value to people with fibromyalgia (<a href="./references#CD012708-bbs2-0035" title="HoffmanDL , SadoskyA , DukesEM , AlvirJ . How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?Pain2010;149(2):194-201. [DOI: 10.1016/j.pain.2009.09.017]">Hoffman 2010</a>; <a href="./references#CD012708-bbs2-0061" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]">Moore 2010b</a>; <a href="./references#CD012708-bbs2-0062" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]">Moore 2010c</a>; <a href="./references#CD012708-bbs2-0063" title="MooreRA , SmugarSS , WangH , PelosoPM , GammaitoniA . Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain2010;151(3):592-7. [DOI: 10.1016/j.pain.2010.07.013]">Moore 2010d</a>; <a href="./references#CD012708-bbs2-0068" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12. [DOI: 10.1111/anae.12148]">Moore 2013a</a>). </p> <p>We assessed publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean a NNTB of 10 or higher; <a href="./references#CD012708-bbs2-0058" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978–0–931092–69–5]">Moore 2008</a>). </p> </section> <section id="CD012708-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We planned to use a fixed‐effect model for meta‐analysis. However, we judged there to be clinical heterogeneity between the studies, and so we used a random‐effects analysis throughout. </p> <p>We undertook quantitative synthesis and present data in forest plots where sufficient data were available. In the event of substantial clinical heterogeneity, we switched off the totals in the forest plots. </p> <p>We undertook a meta‐analysis only if participants, interventions, comparisons, and outcomes were judged to be sufficiently similar to ensure an answer that is clinically meaningful, and only where there were data from at least two studies and 200 participants for analysis. </p> <p>We used Review Manager 5 for meta‐analysis (<a href="./references#CD012708-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>), and Excel for NNTB and NNTH. </p> </section> <section id="CD012708-sec-0036"> <h4 class="title">Quality of the evidence</h4> <p>We used the GRADE approach to assess the quality of evidence related to each of the key outcomes listed in <a href="#CD012708-sec-0020">Types of outcome measures</a> (Chapter 12, <a href="./references#CD012708-bbs2-0034" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), and to interpret findings (<a href="./references#CD012708-bbs2-0031" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383-94. [DOI: 10.1016/j.jclinepi.2011.03.017]">Guyatt 2011</a>; <a href="./references#CD012708-bbs2-0047" title="LangendamMW , AklEA , DahmP , GlasziouP , GuyattG , SchünemannHJ . Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews2013;2:81. [DOI: 10.1186/2046-4053-2-81]">Langendam 2013</a>). The GRADE approach defines the quality of the evidence as the extent of confidence in the estimates of treatment benefits and their safety as follows. </p> <p> <ul id="CD012708-list-0006"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>The GRADE system uses the following criteria for assigning a quality level to a body of evidence (Chapter 12, <a href="./references#CD012708-bbs2-0034" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <p> <ul id="CD012708-list-0007"> <li> <p>High: randomised trials; or double‐upgraded observational studies.</p> </li> <li> <p>Moderate: downgraded randomised trials; or upgraded observational studies.</p> </li> <li> <p>Low: double‐downgraded randomised trials; or observational studies.</p> </li> <li> <p>Very low: triple‐downgraded randomised trials; or downgraded observational studies; or case series/case reports. </p> </li> </ul> </p> <p>Factors that may increase the quality level of a body of evidence are:</p> <p> <ul id="CD012708-list-0008"> <li> <p>large magnitude of effect;</p> </li> <li> <p>all plausible confounding would reduce a demonstrated effect or suggest a spurious effect when results show no effect; </p> </li> <li> <p>dose‐response gradient.</p> </li> </ul> </p> <p>We decreased the grade rating by one (‐ 1) or two (‐ 2) (up to a maximum of ‐ 3 to 'very low') if we identified: </p> <p> <ul id="CD012708-list-0009"> <li> <p>serious (‐ 1) or very serious (‐ 2) limitation to study quality;</p> </li> <li> <p>important inconsistency (‐ 1);</p> </li> <li> <p>some (‐ 1) or major (‐ 2) uncertainty about directness;</p> </li> <li> <p>imprecise or sparse data (‐ 1);</p> </li> <li> <p>high probability of reporting bias (‐ 1).</p> </li> </ul> </p> <p>We considered the following potential reasons to downgrade the quality of evidence (<a href="./references#CD012708-bbs2-0031" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383-94. [DOI: 10.1016/j.jclinepi.2011.03.017]">Guyatt 2011</a>; <a href="./references#CD012708-bbs2-0041" title="HäuserW , KloseP , WelschP , PetzkeF , NothackerM , KoppI . Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain. Schmerz2015;29:8-34. [DOI: 10.1007/s00482-014-1462-y]">Häuser 2015b</a>). </p> <p> <ul id="CD012708-list-0010"> <li> <p>Limitations of study design: where more than 50% of participants were from low‐quality studies as defined by the 'Risk of bias' tool. </p> </li> <li> <p>Inconsistency of results: where point estimates varied widely across studies or CIs of studies showed minimal or no overlap (<a href="./references#CD012708-bbs2-0031" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383-94. [DOI: 10.1016/j.jclinepi.2011.03.017]">Guyatt 2011</a>). </p> </li> <li> <p>Imprecision: where there was only one study or, where there was more than one study, the total number of participants was fewer than 400 or where there were so few data that the results were highly susceptible to the random play of chance (<a href="./references#CD012708-bbs2-0054" title="McQuayHJ , MooreRA . An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998.">McQuay 1998</a>; <a href="./references#CD012708-bbs2-0088" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PLoS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491]">Thorlund 2011</a>). </p> </li> <li> <p>Indirectness: if exclusion of participants with inflammatory rheumatic disease or anxiety and depressive disorders, or both, in the included studies resulted in ≥ 50% of the total patient collective of the systematic review coming from studies in which participants with inflammatory rheumatic or anxiety and depressive disorders, or both, were excluded. This takes into account whether the question being addressed by the systematic review diverged from the available evidence, in terms of the population in routine clinical care. </p> </li> <li> <p>Imputation: if studies used last observation carried forward (LOCF) imputation in circumstances where there were substantial differences in adverse event withdrawals (<a href="./references#CD012708-bbs2-0067" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]">Moore 2012b</a>). </p> </li> <li> <p>Publication bias: where there was potential for publication bias, based on the amount of unpublished data required to make the result clinically irrelevant (<a href="./references#CD012708-bbs2-0058" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978–0–931092–69–5]">Moore 2008</a>), or where there was any concern over selective reporting influencing efficacy or harm estimates. </p> </li> </ul> </p> <p>We paid particular attention to inconsistency, indirectness and imprecision. In addition, circumstances arose where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (<a href="./references#CD012708-bbs2-0032" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso-CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66:151-7. [DOI: 10.1016/j.jclinepi.2010.09.011]">Guyatt 2013a</a>); for example, where one would have no confidence in the result, and would need to downgrade the quality of the evidence by three levels, to very low‐quality. In circumstances where there were no data reported for an outcome, we report the level of evidence as very low‐quality (<a href="./references#CD012708-bbs2-0033" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology2013;66:158-72. [DOI: 10.1016/j.jclinepi.2012.01.012]">Guyatt 2013b</a>). </p> <p>Two review authors (KB, WH) independently made quality ratings separately for each of the 14 outcomes. </p> </section> <section id="CD012708-sec-0037"> <h4 class="title">'Summary of findings' table</h4> <p>We created a 'Summary of findings' table to provide outcome‐specific information concerning the overall quality of evidence from studies included in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes we considered (<a href="./full#CD012708-tbl-0001">summary of findings Table 1</a>). </p> <p><a href="./full#CD012708-tbl-0001">summary of findings Table 1</a> includes outcomes of participant‐reported pain relief of 50% or greater, PGIC (moderate and/or substantial), participant‐reported fatigue and sleep problems, withdrawals due to adverse events, weight gain and serious adverse events. </p> </section> <section id="CD012708-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not plan subgroup analyses since experience of previous reviews indicated that there would be too few data for any meaningful subgroup analysis<i>.</i> </p> </section> <section id="CD012708-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We did not plan sensitivity analyses because the evidence base was known to be too small to allow reliable analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012708-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012708-sec-0040"></div> <section id="CD012708-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD012708-sec-0042"> <h4 class="title">Results of the search</h4> <p>The searches of the four databases (see <a href="https://archie.cochrane.org/sections/documents/view?version=z1710121111395723145906793678650&amp;format=REVMAN#ELECTRONIC_SEARCHES" target="_blank">Electronic searches</a>) retrieved 113 records. Our searches of the trials registers identified two further studies. Our screening of the reference lists of the included publications did not reveal additional randomised controlled trials (RCTs). We therefore had a total of 115 records. Once we removed duplicates, we had a total of 83 records. We excluded 80 records based on titles and abstracts. We obtained the full text of the remaining three records. We added no records to 'Characteristics of studies awaiting classification'. We identified no ongoing studies. For a further description of our screening process, see the study flow diagram (<a href="https://archie.cochrane.org/sections/documents/view?version=z1710121111395723145906793678650&amp;format=REVMAN#FIG-01" target="_blank">Figure 1</a>). </p> <p>We included three studies in the qualitative and quantitative analysis (<a href="#CD012708-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012708-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012708-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012708-sec-0043"> <h4 class="title">Included studies</h4> <p>We included three studies involving 606 participants. See the <a href="./references#CD012708-sec-0112" title="">Characteristics of included studies</a> table for a full description of the studies. </p> <section id="CD012708-sec-0044"> <h5 class="title">Study characteristics</h5> <p>Two studies were conducted in multiple research centres in Japan (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>), and one study was conducted in a single centre in Thailand (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). Two studies were labelled "phase 2b" studies (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>), and one a "phase 3" study (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). All studies had a parallel design. Two studies had a one to two week single‐blind run‐in phase (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). Double‐blind study duration was seven weeks in one study (short‐term study) (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>), and 13 or 14 weeks in two studies (medium‐term studies) (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>; <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). Two studies were started after 2010 (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>), one study was started in 2008 (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> <p>The two Japanese studies were funded by the manufacturer of the respective drug (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). One study did not report on conflicts of interest (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>). One study reported that the authors received payments by the sponsor of the study for consultancies or were employees of the sponsor of the study (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). The Thai study was funded by a public scholarship; authors stated that they had no potential financial conflict of interest (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> </section> <section id="CD012708-sec-0045"> <h5 class="title">Participant characteristics</h5> <p>One study included participants over 18 years old (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>); two included participants between 20 and 64 years (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). Diagnosis of fibromyalgia was established by all studies by the American College of Rheumatology (ACR) 1990 classification criteria (<a href="./references#CD012708-bbs2-0094" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis and Rheumatism1990;33(2):160-72. [DOI: 10.1002/art.1780330203]">Wolfe 1990</a>). All studies required a pain score &gt; 3/10 for inclusion. </p> <p>All studies excluded participants with somatic diseases, including inflammatory rheumatic diseases. Two studies excluded participants with depression and current antidepressant treatment (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). One study excluded participants with major depression (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). There were no reports of participants with anxiety disorders being excluded or not. </p> <p>The median of the mean age was 44 years (range 43 to 45 years; one study included only women; <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). The percentage of female participants in the Japanese studies was 86% and 95%. All participants were Asian (Thai, Japanese). </p> </section> <section id="CD012708-sec-0046"> <h5 class="title">Interventions</h5> <p>Mirtazapine dosage was fixed at 30 mg/d in <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>. Dosing was 15 mg/d, 30 mg/d, or 45 mg/d according to tolerability in <a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>, and 15 mg/d or 30 mg/d according to tolerability in <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>. The rescue medication in <a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a> and <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a> was acetaminophen (paracetamol) up to 1.5 g/day, aspirin up to 300 mg/day, and any nonsteroidal agent (up to 3 days). <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a> did not report on rescue medication. </p> <p>None of the three studies compared mirtazapine with another active drug.</p> </section> </section> <section id="CD012708-sec-0047"> <h4 class="title">Excluded studies</h4> <p>There were no excluded studies.</p> </section> </section> <section id="CD012708-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>In general, the risks of bias of included studies differed between the studies (see <a href="#CD012708-fig-0002">Figure 2</a> and <a href="#CD012708-fig-0003">Figure 3</a> for 'Risk of bias' summary and graph). Detailed information regarding risk of bias assessments of every study are given in the <a href="./references#CD012708-sec-0112" title="">Characteristics of included studies</a> table. One study met the predefined criteria of moderate methodological quality (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>), and two studies had low methodological quality, due to unclear or high risk of bias in seven of eight domains (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>), and in six of eight domains (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> <div class="figure" id="CD012708-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012708-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012708-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012708-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012708-sec-0049"> <h4 class="title">Allocation</h4> <p>Random sequence generation was adequately described and therefore judged at low risk of bias in a single study (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>), and not adequately described and therefore judged at unclear risk of bias in two studies (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> <p>Allocation concealment was adequately described and judged at low risk of bias in a single study (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>), and not adequately described and therefore judged at unclear risk of bias in two studies (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> </section> <section id="CD012708-sec-0050"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel and of outcome assessors was adequately described and judged at low risk of bias in a single study (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>), and not adequately described and therefore of unclear risk of bias in two studies (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> </section> <section id="CD012708-sec-0051"> <h4 class="title">Incomplete outcome data</h4> <p>One study used last observation carried forward (LOCF) to impute missing data and we judged it at unclear risk of bias (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). One study used baseline observation carried forward data for mean pain intensity, which we judged at low risk of bias (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). One study provided completer analysis on request (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>), and we judged it at high risk of bias. </p> </section> <section id="CD012708-sec-0052"> <h4 class="title">Selective reporting</h4> <p>Two studies reported the outcomes as outlined in the protocol, and we judged them to be at low risk of bias (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). One study did not report the outcome 'fatigue' as outlined in the protocol and did not provide the data on request. We judged it to be high risk of bias (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> </section> <section id="CD012708-sec-0053"> <h4 class="title">Sample size bias</h4> <p>We judged sample size to be at low risk of bias in <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a> (≥ 200 participants per treatment arm), and high risk of bias in <a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a> and <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a> (&lt; 50 participants per treatment arm). </p> </section> <section id="CD012708-sec-0054"> <h4 class="title">Group similarity at baseline</h4> <p>We detected no significant differences in demographic and clinical variables at baseline between the study groups (low risk of bias) in two studies (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>; <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). We judged <a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a> to be at high risk of bias because we found a clinically‐relevant difference in baseline variables (duration of fibromyalgia diagnosis). </p> </section> </section> <section id="CD012708-sec-0055"> <h3 class="title" id="CD012708-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD012708-tbl-0001"><b>Summary of findings 1</b> Mirtazapine compared with placebo for adult participants with fibromyalgia</a> </p> <p>We judged there to be clinical heterogeneity between the studies, and so we used a random‐effects analysis throughout. </p> <section id="CD012708-sec-0056"> <h4 class="title">Primary outcomes</h4> <section id="CD012708-sec-0057"> <h5 class="title">Participant‐reported pain relief of 50% or greater</h5> <p>Pain was assessed by the average pain over the last 24 hours recorded in a pain diary on a numeric rating scale 0 to 10 in two studies (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). The other study used a visual analogue scale ranging from 0 to 100 without reporting the time frame (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). The outcome was calculated by an imputation method for <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a> (<a href="./references#CD012708-bbs2-0029" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology2005;20:49-52. [PMID: 15602117]">Furukawa 2005</a>). </p> <p>We entered three studies with 591 participants into an analysis of the risk difference (RD) of participant‐reported pain relief of 50% or greater; it was reported by 71/326 (22%) participants in the mirtazapine and 42/265 (16%) participants in the placebo group. The RD was 0.05 (95% confidence interval (CI) ‐0.01 to 0.12; <a href="./references#CD012708-fig-0007" title="">Analysis 1.1</a>; <a href="#CD012708-fig-0004">Figure 4</a>). According to the predefined criteria, there was no clinically‐relevant benefit from taking mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias . </p> <div class="figure" id="CD012708-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.1 Participant‐reported pain relief of 50% or greater." data-id="CD012708-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.1 Participant‐reported pain relief of 50% or greater. </p> </div> </div> </div> </section> <section id="CD012708-sec-0058"> <h5 class="title">Patient Global Impression of Change (PGIC) 'very much improved'</h5> <p>PGIC was assessed only by one study, reporting the less stringent/easier outcome of 'any improvement' (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). No study reported the number of participants who reported to be much or very much improved. The quality of evidence was very low. </p> </section> <section id="CD012708-sec-0059"> <h5 class="title">Safety (serious adverse events)</h5> <p>Two studies used physical and laboratory tests (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). One study relied on subjective reports of the participants (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> <p>We entered three studies, with 606 participants, into an analysis of serious adverse events. Serious adverse events occurred in 1/334 (0.3%) participants in the mirtazapine group and in 0/271 (0%) in the placebo group. The RD was ‐0.00 (95% CI ‐0.01 to 0.02; <a href="./references#CD012708-fig-0008" title="">Analysis 1.2</a>). According to the predefined criteria, there was no clinically‐relevant harm from taking mirtazapine. The quality of evidence was very low, downgraded due to indirectness and imprecision and risk of publication bias. </p> </section> <section id="CD012708-sec-0060"> <h5 class="title">Tolerability (withdrawals due to adverse events)</h5> <p>Subjective adverse events were assessed by all studies by open questions to the participants. All reported the number of participants dropping out due to adverse events. </p> <p>We entered three studies, with 606 participants, into an analysis of withdrawals due to adverse events. Adverse event withdrawal occurred in 11/334 participants (3.3%) in the mirtazapine group and 8/272 (2.2%) in placebo. The RD was 0.00 (95% CI ‐ 0.02 to 0.03; <a href="./references#CD012708-fig-0009" title="">Analysis 1.3</a>). According to the predefined criteria, there was no clinically‐relevant harm from taking mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> </section> </section> <section id="CD012708-sec-0061"> <h4 class="title">Secondary outcomes</h4> <section id="CD012708-sec-0062"> <h5 class="title">Participant‐reported pain relief of 30% or greater</h5> <p>Pain was assessed by a diary reporting mean pain over the previous 24 hours on a numeric rating scale 0 to 10 in two studies (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). The other used a visual analogue scale ranging from 0 to 100 without reporting the time frame (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). The outcome was calculated by an imputation method for <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a> (<a href="./references#CD012708-bbs2-0029" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology2005;20:49-52. [PMID: 15602117]">Furukawa 2005</a>). </p> <p>We entered three studies, with 591 participants, into an analysis of the RD of participant‐reported pain relief of 30%; it was reported by 154/326 participants (47%) in the mirtazapine group and 89/265 (34%) participants in the placebo group. The RD was 0.13 (95% CI 0.05 to 0.21; <a href="./references#CD012708-fig-0010" title="">Analysis 1.4</a>). The number needed to treat for an additional beneficial outcome (NNTB) was 8 (95% CI 5 to 20). According to the predefined categories, this was a clinically meaningful benefit. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> </section> <section id="CD012708-sec-0063"> <h5 class="title">PGIC 'much improved'</h5> <p>PGIC was assessed only by one study, reporting the less stringent/easier outcome of 'any improvement' (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). The quality of evidence was very low. </p> </section> <section id="CD012708-sec-0064"> <h5 class="title">Participant‐reported sleep problems</h5> <p>We found one study that used the Pittsburgh Sleep Quality Index (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>), one used the Insomnia Severity Index (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>), and one used the Jenkins Sleep Scale (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> <p>We entered three studies, with 573 participants, into an analysis of the effects of mirtazapine on reduction of sleep disturbances. The standardised mean difference (SMD) was ‐0.23 (95% CI ‐0.39 to ‐0.06). Based on Cohen's categories, the effect on fatigue of mirtazapine versus placebo was small (<a href="./references#CD012708-fig-0011" title="">Analysis 1.5</a>). According to the predefined categories, there was a clinically meaningful benefit from taking mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> </section> <section id="CD012708-sec-0065"> <h5 class="title">Participant‐reported fatigue</h5> <p>Fatigue was assessed by the single item of the Fibromyalgia Impact Questionnaire (FIQ; visual analogue scale 0 to 10) in two studies (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>), but one did not report this outcome (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). The other used the subscale 'vitality' of the Short Form Health Survey 36 (VAS 0 to 100) (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). </p> <p>We entered two studies with 533 participants into an analysis of the effects of mirtazapine on fatigue. The SMD was ‐0.02 (95% CI ‐0.19 to 0.16; <a href="./references#CD012708-fig-0012" title="">Analysis 1.6</a>). According to the predefined criteria, there was no clinically‐relevant benefit from taking mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> </section> <section id="CD012708-sec-0066"> <h5 class="title">Participant‐reported mean pain intensity</h5> <p>Pain intensity was assessed by a diary reporting mean pain over the previous 24 hours on a numeric rating scale 0 to 10 in two studies (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). One study used a visual analogue scale ranging from 0 to 100 without reporting the time frame (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> <p>We entered three studies, with 591 participants, into an analysis of the effects of mirtazapine on pain intensity reduction. The SMD was ‐0.29 (95% CI ‐0.46 to ‐0.13). According to Cohen's categories the effect on pain of mirtazapine compared to placebo was small (<a href="./references#CD012708-fig-0013" title="">Analysis 1.7</a>). According to the predefined categories there was a clinically meaningful benefit from taking mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> </section> <section id="CD012708-sec-0067"> <h5 class="title">Participant‐reported improvement of health‐related quality of life (HRQoL) of 20% or greater </h5> <p>All studies used the total score of the Fibromyalgia Impact Questionnaire (FIQ). The responder rates were calculated for all studies by an imputation method (<a href="./references#CD012708-bbs2-0029" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology2005;20:49-52. [PMID: 15602117]">Furukawa 2005</a>). </p> <p>We entered three studies, with 586 participants, into an analysis of the effects of mirtazapine on HRQoL. Improvement of HRQoL of 20% or greater was reported by 188/324 participants (58%) in the mirtazapine group and 131/262 (50%) participants in the placebo group. The RD was 0.08 (95% CI ‐0.01 to 0.16; <a href="./references#CD012708-fig-0014" title="">Analysis 1.8</a>). According to the predefined criteria, there was no clinically‐relevant benefit by mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> </section> <section id="CD012708-sec-0068"> <h5 class="title">Participant‐reported negative mood</h5> <p><a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a> used the Hamilton Depression Rating Scale (HDRS). The other studies used the Beck Depression Inventory (BDI) II. </p> <p>We entered three studies, with 588 participants, into an analysis of the effects of mirtazapine on the reduction of negative mood. The SMD was ‐0.67 (95% CI ‐1.44 to 0.10; <a href="./references#CD012708-fig-0015" title="">Analysis 1.9</a>). According to the predefined criteria, there was no clinically‐relevant benefit from taking mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> </section> <section id="CD012708-sec-0069"> <h5 class="title">Withdrawals due to lack of efficacy</h5> <p>This adverse event was reported by all studies.</p> <p>We entered three studies, with 605 participants into an analysis of withdrawals due to lack of efficacy; 5/333 participants (1.5%) dropped out due to lack of efficacy in the mirtazapine group and 0/271 (0%) in the placebo group. The RD was 0.01 (95% CI ‐0.01 to 0.02; <a href="./references#CD012708-fig-0016" title="">Analysis 1.10</a>). According to the predefined criteria, there was no clinically‐relevant harm from taking mirtazapine. The quality of evidence was very low, downgraded due to indirectness and imprecision and risk of publication bias. </p> </section> <section id="CD012708-sec-0070"> <h5 class="title">Participants reporting any adverse event</h5> <p>This adverse event was reported by all studies.</p> <p>We entered three studies, with 606 participants, into an analysis of at least one adverse event; 255/334 participants (76%) reported at least one adverse event in the mirtazapine group and 159/272 (59%) in the placebo group. The RD was 0.12 (95% CI ‐0.01 to 0.26; <a href="./references#CD012708-fig-0017" title="">Analysis 1.11</a>). According to the predefined criteria, there was no clinically‐relevant harm from taking mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> </section> <section id="CD012708-sec-0071"> <h5 class="title">Specific adverse events</h5> <section id="CD012708-sec-0072"> <h6 class="title">Somnolence</h6> <p>This adverse event was reported by all studies.</p> <p>We entered three studies, with 606 participants, into an analysis of somnolence as an adverse event; 138/334 participants (42%) reported somnolence in the mirtazapine group and 37/272 (14%) in the placebo group. The RD was 0.24 (95% CI 0.18 to 0.30; <a href="./references#CD012708-fig-0018" title="">Analysis 1.12</a>; <a href="#CD012708-fig-0005">Figure 5</a>). The number needed to treat for an additional harmful outcome (NNTH) from taking mirtazapine was 5 (95% CI 3 to 6) . According to the predefined categories, there was a clinically meaningful harm from taking mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> <div class="figure" id="CD012708-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.12 Specific adverse event (somnolence)." data-id="CD012708-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.12 Specific adverse event (somnolence). </p> </div> </div> </div> </section> <section id="CD012708-sec-0073"> <h6 class="title">Weight gain</h6> <p>This adverse event was reported by all studies.</p> <p>We entered three studies, with 606 participants, into an analysis of weight gain as an adverse event; 63/334 (19 %) of participants in the mirtazapine group had weight gain recorded as an adverse event and 3/272 (1.1%) in the placebo group. The RD was 0.17 (95% CI 0.11 to 0.23; <a href="./references#CD012708-fig-0019" title="">Analysis 1.13</a>; <a href="#CD012708-fig-0006">Figure 6</a>). The NNTH by taking mirtazapine was 6 (95% CI 5 to 10). According to the predefined categories, there was a clinically meaningful harm from taking mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> <div class="figure" id="CD012708-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.14 Specific adverse event (elevated alanine aminotransferase)." data-id="CD012708-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.14 Specific adverse event (elevated alanine aminotransferase). </p> </div> </div> </div> <p>One study reported an average weight gain of 4.5 kg within 13 weeks with mirtazapine 30 mg/d group, 2 kg with mirtazapine 15 mg/d group, and 1 kg with placebo (<a href="./references#CD012708-bbs2-0003" title="YeephuS , SuthisisangC , SuttiruksaS , PrateepavanichP , LimampaiP , RussellIJ . Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. The Anals of Pharmacotherapy2013;47:921-31. ">Yeephu 2013</a>). </p> </section> <section id="CD012708-sec-0074"> <h6 class="title">Elevated alanine aminotransferase</h6> <p>The outcome was reported by two studies (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). </p> <p>We entered two studies, with 566 participants, into an analysis of elevated alanine aminotransferase as an adverse event; 41/307 participants (13%) in the mirtazapine group and 5/259 (1.9%) in the placebo group had an elevated alanine aminotransferase recorded. The RD was 0.13 (95% CI 0.04 to 0.22; <a href="./references#CD012708-fig-0020" title="">Analysis 1.14</a>). The NNTH by taking mirtazapine was 8 (95% CI 5 to 25). According to the predefined categories, there was a clinically meaningful harm from taking mirtazapine. The quality of evidence was low, downgraded due to indirectness and risk of publication bias. </p> </section> </section> <section id="CD012708-sec-0075"> <h5 class="title">Investigation of heterogeneity</h5> <p>There was high statistical heterogeneity in the outcome of fatigue, any adverse event, and elevated alanine aminotransferase. We did not find any obvious clinical reasons for this heterogeneity. </p> </section> <section id="CD012708-sec-0076"> <h5 class="title">Publication bias</h5> <p>We tested the largest efficacy estimate of pain relief of 30% or greater for the potential for publication bias (<a href="./references#CD012708-bbs2-0058" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978–0–931092–69–5]">Moore 2008</a>). We calculated that 149 extra participants would have had to have been included in entirely negative trials (zero treatment effect) to move the NNTB for pain relief of 30% or greater from 8 to our limit for clinical utility of 10. That is only 25% of the number of participants involved in the calculation, and we judged the potential for publication bias to be high. </p> <p>Because there was a significant risk of publication bias for an important secondary efficacy outcome, and because publication bias could affect all outcomes, we downgraded our estimation of evidence quality by at least one category for all outcomes. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012708-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012708-sec-0077"></div> <section id="CD012708-sec-0078"> <h3 class="title" id="CD012708-sec-0078">Summary of main results</h3> <p>The tetracyclic antidepressant, mirtazapine, did not show a statistically significant benefit compared to placebo in participant‐reported pain relief of 50% or greater, in participant‐reported improvement of health‐related quality of life (HRQoL) of 20% or greater, or in reduction of fatigue and negative mood. Mirtazapine showed a clinically‐relevant benefit compared to placebo in participant‐reported pain relief of 30% or greater and in the reduction of mean pain intensity and of sleep problems. There were no statistically significant differences between mirtazapine and placebo in the frequency of withdrawals due to adverse events or due to lack of efficacy and of serious adverse events. There was a clinically‐relevant harm from taking mirtazapine compared to placebo in the number of participants with somnolence, weight gain, and elevated alanine aminotransferase. </p> <p>There is low‐quality evidence that some people with fibromyalgia will experience moderate pain relief and reduced sleep problems from taking mirtazapine. However, the potential benefits might be outweighed by the potential harms (somnolence, weight gain). </p> </section> <section id="CD012708-sec-0079"> <h3 class="title" id="CD012708-sec-0079">Overall completeness and applicability of evidence</h3> <p>We cannot rule out the possibility that negative study results have not been published or have been missed by our search strategy. An additional 25% of participants in zero effect studies would eliminate any clinical relevance for the largest efficacy effect, that of at least 30% pain relief. </p> <p>The applicability (external validity) of evidence is limited for the following reasons.</p> <p> <ul id="CD012708-list-0011"> <li> <p>The studies were performed in research centres and not in routine clinical care. The efficacy of drug therapies in fibromyalgia seems to be higher in the context of randomised controlled trials (RCTs) than in routine clinical care (<a href="./references#CD012708-bbs2-0099" title="WolfeF , WalittBT , KatzRS , LeeYC , MichaudKD , HäuserW . Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. European Journal Pain2013;17:581-6. [10.1002/j.1532-2149.2012.00234.x]">Wolfe 2013b</a>). </p> </li> <li> <p>The substantial placebo response rate seen across all of the mirtazapine trials impedes the appraisal of the efficacy of mirtazapine in fibromyalgia. However, the high placebo response rates seen with mirtazapine have been observed in all fibromyalgia drug trials (<a href="./references#CD012708-bbs2-0036" title="HäuserW , KossevaM , ÜceylerN , KloseP , SommerC . Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis. Arthritis Care and Research2011;63:808-20. [DOI: 10.1002/acr.20328]">Häuser 2011</a>; <a href="./references#CD012708-bbs2-0037" title="HäuserW , JungE , Erbslöh-MöllerB , GesmannM , Kühn-BeckerH , PetermannF , et al. German fibromyalgia consumer reports. Benefits and harms of fibromyalgia syndrome therapies. Schmerz2012;26(2):150-9. [DOI: 10.1007/s00482-012-1161-5]">Häuser 2012</a>). </p> </li> <li> <p>The exclusion criteria were strict. Some concomitant medications commonly used to treat fibromyalgia symptoms were not permitted in the included studies. This excluded a large number of participants who were unwilling, or unable, to come off medications, such as other antidepressants and anticonvulsants. For this reason, participant selection in the RCTs was biased towards recruiting participants with less severe symptoms than are seen in the community (<a href="./references#CD012708-bbs2-0028" title="Fuller-ThomsonE , Nimigon-YoungJ , BrennenstuhlS . Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey. Rheumatology International2012;32:853-62. [DOI: 10.1007/s00296-010-1713-x]">Fuller‐Thomson 2012</a>). Participants with other medical disorders, such as inflammatory rheumatic diseases, which are frequently associated with fibromyalgia, were also excluded. The study results cannot be applied to people with so‐called secondary fibromyalgia (associated with inflammatory rheumatic diseases; <a href="./references#CD012708-bbs2-0015" title="ClauwDJ , KatzP . The overlap between fibromyalgia and inflammatory rheumatic disease: when and why does it occur?Journal of Clinical Rheumatology1995;1:335-42.">Clauw 1995</a>). The largest study excluded all potential participants with major depression (<a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>), though this is frequently associated with fibromyalgia (<a href="./references#CD012708-bbs2-0028" title="Fuller-ThomsonE , Nimigon-YoungJ , BrennenstuhlS . Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey. Rheumatology International2012;32:853-62. [DOI: 10.1007/s00296-010-1713-x]">Fuller‐Thomson 2012</a>). </p> </li> <li> <p>The majority of included participants were Japanese women between 20 and 64 years. Compared to studies with Food and Drug Administration (FDA) approved medications for fibromyalgia (duloxetine, milnacipran, pregabalin; <a href="./references#CD012708-bbs2-0020" title="DerryS , CordingM , WiffenPJ , LawS , PhillipsT , MooreRA . Pregabalin for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD011790. [DOI: 10.1002/14651858.CD011790.pub2]">Derry 2017</a>; <a href="./references#CD012708-bbs2-0038" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD010292. [DOI: 10.1002/14651858.CD010292]">Häuser 2013a</a>), in which North American and European participants prevailed, the low number of participants dropping out of the studies due to adverse events in the mirtazapine studies is astonishing. We do not know if the study results are valid for other races, adolescents, men and participants &gt; 64 years. </p> </li> <li> <p>The long‐term efficacy and safety of mirtazapine in fibromyalgia cannot be assessed by the studies included in the review. We did not find long‐term, open‐label extension studies with mirtazapine in our searches. </p> </li> <li> <p>The place of mirtazapine compared to other drugs and nonpharmacological therapies in the treatment of fibromyalgia symptoms still needs to be determined. </p> </li> </ul> </p> </section> <section id="CD012708-sec-0080"> <h3 class="title" id="CD012708-sec-0080">Quality of the evidence</h3> <p>The quality of evidence ranks from low to very low across the different outcomes. The likelihood that the effect could be substantially different is high. The main limiting factors, which were the reason for downgrading confidence in all outcomes, were indirectness and the potential for publication bias, though high risk of bias in two of the three studies and small numbers of events for some outcomes also contributed. In addition, two of the included studies were sponsored by pharmaceutical companies (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>; <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>). We assessed the quality of evidence in this review on the data presented in peer reviewed journals, published clinical trial date (<a href="./references#CD012708-bbs2-0001" title="JapicCTI-101176. A double-blind, placebo-controlled phase II study of Org 3770 (mirtazapine) in patients with fibromyalgia. clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101176 June 29, 2010. ">JapicCTI‐101176</a>), and some additional details provided on request by the pharmaceutical companies or principal investigators. However, not all requested data were provided, so we had to calculate some standard deviations (SDs) and outcomes. </p> </section> <section id="CD012708-sec-0081"> <h3 class="title" id="CD012708-sec-0081">Potential biases in the review process</h3> <p>We searched for unpublished studies with mirtazapine, but cannot be certain that we identified all other studies that might have been performed but not published. </p> <p>We may have overestimated the risk of bias of some studies that were carried out to the highest standards, but did not report some details of methodology (e.g. randomisation and blinding procedures). </p> <p>Some included studies used statistical methods (last observation carried forward (LOCF)) that may bias results towards exaggerating the efficacy of drugs (<a href="./references#CD012708-bbs2-0067" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]">Moore 2012b</a>). We could not assess the potential effects, nor allow for any possible bias in the use of these methods. We considered the study not to be at high risk as the adverse event withdrawal rates for mirtazapine and placebo were low (around 3%) and not very different (<a href="./references#CD012708-bbs2-0067" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]">Moore 2012b</a>). </p> <p>The influence of permitted cointerventions (e.g. rescue medication) on positive effects and adverse events was unclear because type and dosage of cointerventions were neither clearly reported nor controlled for. The type and dose of permitted cointerventions (e.g. rescue medication) was not clearly reported, so we were unable to assess their influence on outcomes of either efficacy or harm. </p> <p>This review included 606 participants. To capture rare and potentially severe adverse events would require a much larger data set, e.g. to capture an adverse event with a frequency of 1:100,000, 300,000 patient‐observations would be necessary (<a href="./references#CD012708-bbs2-0004" title="AndersohnF , GarbeE . Pharmacoepidemiological research with large health databases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz2008;51:1135-44. [DOI: 10.1007/s00103-008-0648-9]">Andersohn 2008</a>). Rare complications of mirtazapine include hyponatraemia (<a href="./references#CD012708-bbs2-0089" title="ViramontesTS , TruongH , LinneburSA . Antidepressant-induced hyponatremia in older adults. The Consultant Pharmacist2016;31:139-50. [DOI: 10.4140/TCP.n.2016.139 ]">Viramontes 2016</a>), leucopenia (<a href="./references#CD012708-bbs2-0014" title="CivalierKA , KrahnLE , AgrwalN . Repeated episodes of neutropenia triggered by mirtazapine. Psychosomatics2009;50:299-300. [DOI: 10.1176/appi.psy.50.3.299 ]">Civalier 2009</a>), and gastrointestinal bleeding (<a href="./references#CD012708-bbs2-0074" title="NaKS , JungHY , ChoSJ , ChoSE . Can we recommend mirtazapine and bupropion for patients at risk for bleeding? A systematic review and meta-analysis. Journal of Affective Disorders2017;225:221-6. [PMID: 28841484]">Na 2017</a>). </p> </section> <section id="CD012708-sec-0082"> <h3 class="title" id="CD012708-sec-0082">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of another systematic review on mirtazapine in fibromyalgia. We cannot confirm the conclusion of an uncontrolled trial that mirtazapine is an effective and promising treatment in fibromyalgia (<a href="./references#CD012708-bbs2-0083" title="SamborskiW , Lezańska-SzperaM , RybakowskiJK . Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry2004;37(4):168-70. [DOI: 10.1055/s-2004-827172]">Samborski 2004</a>). The high incidence of weight gain and elevated liver enzymes with mirtazapine in fibromyalgia is in line with studies of mirtazapine in other chronic pain syndromes (<a href="./references#CD012708-bbs2-0082" title="RiedigerC , SchusterT , BarlinnK , MaierS , WeitzJ , SiepmannT . Adverse effects of antidepressants for chronic pain: a systematic review and meta-analysis. Frontiers in Neurology2017;8:307. [DOI: 10.3389/fneur.2017.00307]">Riediger 2017</a>), and in depression (<a href="./references#CD012708-bbs2-0091" title="WatanabeN , OmoriIM , NakagawaA , CiprianiA , BarbuiC , ChurchillR , et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD006528. [DOI: 10.1002/14651858.CD006528]">Watanabe 2011</a>). Nausea, vomiting and sexual dysfunction have been less frequently found in mirtazapine than in selective serotonin reuptake inhibitor (SSRI) and serotonin and norephinephrin reuptake inhibitor (SNRI) trials in depression and point to a unique adverse event profile of mirtazapine (<a href="./references#CD012708-bbs2-0091" title="WatanabeN , OmoriIM , NakagawaA , CiprianiA , BarbuiC , ChurchillR , et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD006528. [DOI: 10.1002/14651858.CD006528]">Watanabe 2011</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012708-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012708-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012708-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012708-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.1 Participant‐reported pain relief of 50% or greater." data-id="CD012708-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.1 Participant‐reported pain relief of 50% or greater. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.12 Specific adverse event (somnolence)." data-id="CD012708-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.12 Specific adverse event (somnolence). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.14 Specific adverse event (elevated alanine aminotransferase)." data-id="CD012708-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mirtazapine versus placebo at the end of treatment, outcome: 1.14 Specific adverse event (elevated alanine aminotransferase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 1: Participant‐reported pain relief of 50% or greater" data-id="CD012708-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 1: Participant‐reported pain relief of 50% or greater </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 2: Safety (serious adverse events)" data-id="CD012708-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 2: Safety (serious adverse events) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 3: Tolerability (dropouts due to adverse events)" data-id="CD012708-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 3: Tolerability (dropouts due to adverse events) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 4: Participant‐reported pain relief of 30% or greater" data-id="CD012708-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 4: Participant‐reported pain relief of 30% or greater </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 5: Participant‐reported sleep problems" data-id="CD012708-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 5: Participant‐reported sleep problems </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 6: Participant‐reported fatigue" data-id="CD012708-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 6: Participant‐reported fatigue </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 7: Participant‐reported mean pain intensity" data-id="CD012708-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 7: Participant‐reported mean pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 8: Participant‐reported improvement of HRQoL by 20% or more" data-id="CD012708-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 8: Participant‐reported improvement of HRQoL by 20% or more </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 9: Participant‐reported negative mood" data-id="CD012708-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 9: Participant‐reported negative mood </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 10: Withdrawals due to lack of efficacy" data-id="CD012708-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 10: Withdrawals due to lack of efficacy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 11: Participants with any adverse event" data-id="CD012708-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 11: Participants with any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 12: Specific adverse event (somnolence)" data-id="CD012708-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 12: Specific adverse event (somnolence) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 13: Specific adverse event (weight gain)" data-id="CD012708-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 13: Specific adverse event (weight gain) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012708-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/urn:x-wiley:14651858:media:CD012708:CD012708-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 14: Specific adverse event (elevated alanine aminotransferase)" data-id="CD012708-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_t/tCD012708-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Mirtazapine versus placebo at the end of treatment, Outcome 14: Specific adverse event (elevated alanine aminotransferase) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/media/CDSR/CD012708/image_n/nCD012708-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012708-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mirtazapine compared with placebo for adult participants with fibromyalgia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Mirtazapine compared with placebo for adult participants with fibromyalgia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adult participants with fibromyalgia </p> <p><b>Settings:</b> study centres </p> <p><b>Intervention:</b> mirtazapine 15 mg/d to 45 mg/d </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> <p><b>(study duration of 7 to 13 weeks)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Probable outcome with mirtazapine<br/>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Probable outcome with placebo (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 50% or greater (substantial improvement)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>218 (200 to 236) per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 (145 to 171) per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.05</p> <p>(‐0.01 to 0.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB not calculated due to lack of statistically significant difference between mirtazapine and placebo </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety: serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 event in 334 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 event ins 271 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.00</p> <p>(‐0.01 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>606</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meaningful calculations not possible with a single event</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolerability: withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 (30 to 39) per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 (20 to 24) per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.01</p> <p>(‐0.02 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>606</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB not calculated due to lack of statistically significant difference between mirtazapine and placebo </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 30% or greater (moderate improvement)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>472 (434 to 510) per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>336 (309 to 363) per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.13 (0.05 to 0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB was 8 (95% CI 5 to 20). Only 149 extra participants in trials of zero treatment effect to move NNTB for pain relief of 30% or greater from 8 to limit for clinical utility of 10 (25% of total number available) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported sleep problems</p> <p>(scale: 0 to 28; higher scores indicate more sleep problems)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean sleep problems<br/>score was 4.9 points<br/>lower (1.3 to<br/>8.3 points lower) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean score 11.4 (SD 5.9)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.23</p> <p>(‐0.39 to ‐0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>573</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 10 (95% CI 7 to 12)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Somnolence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>423 (389 to 457) per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 (125 to 147) per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.24 (0.18 to 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>606</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 5 (95% CI 3 to 6)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 (180 to 200) per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000 (not calculated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.17</p> <p>(0.11 to 0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>606</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 6 (95% 5 to 9)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional benefit; <b>NNTH:</b> number needed to treat for an additional harm; <b>PGIC:</b> Patient Global Impression of Change; <b>RD:</b> risk difference;<b>SMD</b>: standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p>High quality: we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p>Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> <p>Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p>Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice for indirectness (participants with inflammatory rheumatic diseases and depressive disorders excluded in &gt; 50% of studies) and risk of publication bias.<br/><sup>b</sup>Downgraded three times for imprecision due to low event rate, indirectness, and risk of publication bias.<br/><sup>c</sup>From <a href="./references#CD012708-bbs2-0002" title="MikiK , MurakamiM , OkaH , OnozawaK , YoshidaS , OsadaK . Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain2016;157(9):2089-96. ">Miki 2016</a>; N = 422 participants; Japanese version of the Insomnia severity index. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mirtazapine compared with placebo for adult participants with fibromyalgia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/full#CD012708-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012708-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mirtazapine versus placebo at the end of treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Participant‐reported pain relief of 50% or greater <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.01, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Safety (serious adverse events) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Tolerability (dropouts due to adverse events) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.02, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Participant‐reported pain relief of 30% or greater <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.05, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Participant‐reported sleep problems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.39, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Participant‐reported fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.19, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Participant‐reported mean pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.46, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Participant‐reported improvement of HRQoL by 20% or more <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.01, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Participant‐reported negative mood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐1.44, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Participants with any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.01, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Specific adverse event (somnolence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.18, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Specific adverse event (weight gain) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.11, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Specific adverse event (elevated alanine aminotransferase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.04, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mirtazapine versus placebo at the end of treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012708.pub2/references#CD012708-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012708.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012708-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012708-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012708-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012708-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012708-note-0004">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012708-note-0003">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012708\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012708\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012708\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012708\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012708\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012708.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012708.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012708.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012708.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012708.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726227496"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012708.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726227499"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012708.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8e800af9f431',t:'MTc0MDcyNjIyNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 